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Abstract 
 
The role of adenosine as an endogenous neuromodulator is well established, but the 
mechanism(s) mediating the extensive modulatory and regulatory actions of adenosine have 
not yet been fully elucidated. In fact, although adenosine, through activation of adenosine 
A1 and A2A receptors, has been demonstrated as neuroprotective or neurodegenerative, 
respectively, little is known about the mechanism by which adenosine mediates these 
actions. In the hippocampus, essential physiological processes rely on adenosine signaling, 
including regulation of long-term potentiation (LTP) and long-term depression (LTD). 
Neuromodulation by adenosine is dominantly inhibitory in the hippocampus, mediated by 
the abundant and high-affinity adenosine A1 receptor. In ischemia and hypoxia, A1 receptor 
activation induces rapid synaptic depression which is mediated by multiple signaling 
pathways including the induction of excitatory AMPA glutamate receptor internalization, 
which inhibits synaptic transmission in the hippocampus. Considerable effort has been 
devoted to investigating the role of adenosine in ischemic stroke, due to the fact that in 
cerebral ischemia or hypoxia, extracellular levels of adenosine increase dramatically. This 
thesis explores the functional consequences of adenosine signaling in hypoxia and ischemia, 
which mediate GluA1 AMPA receptor subunit internalization. Three major serine/threonine 
protein phosphatases (PPs), PP1, PP2A, and PP2B are investigated and shown to mediate 
A1 receptor-mediated GluA1 internalization in hypoxic conditions in the rat hippocampus. 
Further experiments demonstrate the role of adenosine A2A receptors in potentiating 
hippocampal synaptic transmission in reperfusion by increasing GluA1 surface expression 
through increased phosphorylation of regulatory C-terminal phosphorylation sites of GluA1. 
The mechanism of extracellular adenosine regulation by equilibrative nucleoside 
transporters (ENTs) and casein kinase 2 (CK2) are examined and shown to interact in 
hypoxia/reperfusion experiments on hippocampal slices. Finally, using a pial vessel 
disruption (PVD) permanent focal cortical ischemia stroke model, experiments demonstrate 
increased adenosine tone in the hippocampus, which mediates increased adenosine-induced 
synaptic depression. CK2 inhibition was also neuroprotective after 20min hypoxia. This 
shows that adenosine tone is increased in the hippocampus after a small cortical stroke, 
implying a potential global effect of focal ischemia. Together, these studies further reveal 
the paramount role of adenosine as a neuromodulator in the hippocampus during neuronal 
insults, furthering our understanding of the mechanism of neuronal death in hypoxic and 
ischemic conditions.   
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Chapter 1: Introduction 
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1.1 Introduction  
Stroke is becoming an increasingly common disease and has become a major healthcare 
issue. It is the leading cause of disability in North America and also the third leading cause of 
death (Marler et al., 2000). Stroke rehabilitation is a substantial, long-term cost on the 
healthcare system, and an improvement from current therapies is urgently needed (Pantoni, 
2010). Numerous resources have been devoted to developing effective neuroprotective stroke 
therapies, with little success thus far in clinical trials (Gladstone et al., 2002; Ikonomidou and 
Turski, 2002; Ali et al., 2013). In fact, currently only one treatment has been approved for 
stroke, which is the use of recombinant tissue plasminogen activator (rt-PA) to resolve a 
stroke-causing vascular clot in the brain (Friedman et al., 1996). Unfortunately, rt-PA is a 
relatively ineffective therapy, working in only a small percentage of stroke patients (~3%), 
largely due to the limited time window for treatment (~90-180 minutes), and can induce 
intracranial hemorrhage in a small number of patients (Marler et al., 2000). There has also 
been question as to whether rt-PA was initially approved based on a misinterpretation of 
clinical trial data (Mann, 2002). Hence, characterization of new therapeutic targets for 
neuroprotective stroke therapy is critical.  
To successfully define a therapeutic target for neuroprotection in neuronal insults such as 
stroke, an in-depth understanding of the cellular mechanisms contributing to neuronal 
damage vs. survival in stroke is necessary. A stroke can be classified as either hemorrhagic, 
where a blood vessel ruptures and bleeds into the skull, or ischemic, where there is a 
disruption to blood flow to tissue in the brain and account for about 85% of all stroke cases 
(Friedman et al., 1996; Lammie, 2000). Ischemic stroke is characterized by a reduction in 
blood flow to an area of the brain caused by a clot or stenosis (Marler et al., 2000). Reduced 
blood flow lowers oxygen and nutrient delivery to the ischemic brain tissue, inducing a 
number of compensatory mechanisms in an attempt to protect the neurons, such as the 
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activation of adenosine receptors, which is thought to be dominantly neuroprotective 
(Rudolphi et al., 1992; Wardas, 2002).  
Two major components form in the brain due to ischemia: one being the ischemic core 
where brain tissue loses all perfusion and there is widespread cell death (necrosis). The other 
component is the ischemic penumbra, an area surrounding the ischemic core with insufficient 
perfusion but where the tissue may be salvageable if effective therapeutic interventions are 
developed. Neurons in the ischemic penumbra are susceptible to death through various 
mechanisms such as apoptosis (Sirén et al., 2001; Hardingham et al., 2002), excitotoxicity 
(Sommer et al., 2006), glial cell dysfunction (Largo et al., 1996), and oxidative stress 
(Murakami et al., 1998),. The ischemic penumbra is currently a major target in stroke therapy 
development, with research focusing on rescuing penumbral tissue before the onset of 
neuronal death (Schiff and Somjen, 1987).  
A major goal in this laboratory is to gain an improved understanding of the mechanism by 
which apoptosis occurs in ischemic tissue using hypoxia to simulate stroke conditions. 
Specifically, we examine the role of adenosine in the neuronal response to hypoxic conditions 
in the hippocampus. We recently implicated adenosine, an endogenous purine nucleoside, in 
the reduction of synaptic transmission in the hippocampus by regulation of the surface 
expression of α-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid (AMPA) receptors 
(Chen et al., 2014). This thesis examines the adenosine-mediated internalization of the 
AMPA receptor subunit GluA1, which accompanies adenosine-induced synaptic depression 
in hypoxia. Additionally, we examine the role of casein kinase 2 (CK2) and equilibrative 
nucleoside transporters (ENTs) in the regulation of extracellular adenosine levels and their 
interaction with adenosine A1 receptors. Both protein phosphatase and CK2 drug modulators 
are then tested for potential neuroprotection to hippocampal slices subjected to a hypoxic 
insult (20min). Finally, using an in vivo pial vessel disruption focal cortical ischemia rat 
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model (PVD), we reveal evidence showing that focal cortical ischemia may have global 
effects in regions as far away from the lesion as the hippocampus. This chapter reviews 
important background literature about the key experiments performed in subsequent chapters.  
 
1.2 Adenosine in the brain 
Adenosine is a purine nucleoside required for cell survival. It is comprised of an adenine 
molecule attached to a ribose sugar, and has the potential to be phosphorylated. It plays an 
essential role in multiple cellular processes, such as cellular energy transfer and intracellular 
signaling (Collis and Hourani, 1993). In energy transfer processes, adenosine is conjugated 
with up to three phosphates, and is then known as adenosine monophosphate (AMP), 
adenosine diphosphate (ADP), and adenosine triphosphate (ATP). Hydrolysis of these 
phosphorylated molecules releases energy that is utilized by almost all energy-requiring 
cellular processes in mammals, including widely in the brain(Zur Nedden et al., 2011). Due to 
the ubiquitous nature of adenosine, mammalian cells have developed the ability to use 
adenosine and other adenine nucleotides as signaling molecules (Collis and Hourani, 1993).  
As a neuromodulator, adenosine modulates a wide array of physiological processes 
(Fredholm et al., 2000; Fredholm et al., 2005). A major consequence of adenosine signaling 
is the ability for adenosine to induce intracellular changes in metabolically stressed cells to 
restore energy balance, and has therefore been termed a retaliatory metabolite (Fredholm et 
al., 2005). Table 1.1 outlines examples of physiological consequences of adenosine signaling 
in the human body. 
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Table 1.1. Examples of the actions of adenosine throughout the body.  
Physiological System  Examples of actions induced by adenosine 
Central Nervous system Modulation of neurotransmitter releasea,g 
 
Sedationg 
 
Modulation of synaptic transmissiona,g 
  Modulation of locomotor activityb,g 
Gastrointestinal Tract Reduces stomach acid secretion 
  Modulation of GI tone and secretions 
Cardiovascular System Vasoconstriction and vasodilationc 
 
Bradycardia 
 
Platelet inhibition 
 
Negative cardiac inotropy 
  Angiogenesish 
Renal Function Modulation of glomerular filtrationb  
 
Mesangial cell contraction 
 
Antidiuresis 
  Inhibition of renin releaseb 
Metabolism Reduces lipolysis 
 
Increases glucose uptake 
 
Increases insulin sensitivity 
  Increases gluconeogenesis 
Respiratory System Bronchoconstriction - implicated in asthma 
 
Mucus secretion 
  Respiratory depression 
Immune System Immunosuppression 
 
Neutrophil modulation 
  Mast cell degranulation 
 
Physiological functions reviewed in: a - (Cunha, 2005), b- (Collis and Hourani, 1993),  
c- (Feoktistov and Biaggioni, 1997), d- (Espinal et al., 1983), e- (Latini et al., 1996a),  
f- (Hershfield, 2005), g-(Fredholm et al., 2005), h-(Feoktistov et al., 2002) 
 
Adenosine has been recognized as a major neuromodulator in both physiological and 
pathophysiological conditions (Rudolphi and Schubert, 1995; Fredholm et al., 2005). Recent 
advances in adenosine research have profoundly improved our understanding of the complex 
role that adenosine plays in the brain, yet a considerable amount remains unknown. 
Adenosine acts dominantly as an inhibitory neuromodulator, inducing reduced synaptic 
transmission when extracellular adenosine levels increase, which occurs during hypoxic or 
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ischemic events (Rudolphi and Schubert, 1995). A basal adenosine tone is maintained in 
physiological conditions and contributes to basal inhibitory tone in the hippocampus 
(Brundege and Dunwiddie, 1996). Substantial evidence suggests a neuroprotective role for 
adenosine in hypoxia/ischemia due to its ability to reduce synaptic transmission and prevent 
excitotoxic cell death (Rudolphi and Schubert, 1995; Sebastião et al., 2001; Cunha, 2005). 
Adenosine receptors comprise of a group of four receptor subtypes (A1, A2A, A2B, A3), 
which are differentially expressed in the brain, each having unique physiological functions 
(Dunwiddie and Masino, 2001).  
 
1.3 Adenosine receptor subtypes and functions 
Adenosine interacts with four G-protein-coupled adenosine receptor subtypes known as 
A1, A2A, A2B, and A3 (Collis and Hourani, 1993; Fredholm et al., 2000). These receptors 
are present in the plasma membrane of the cell and transduce intracellular signals through 
various G protein-coupled mechanisms. Each receptor subtype is encoded by different genes 
and have a conserved structure, forming a functional 7-transmembrane region receptor 
(Collis and Hourani, 1993). Adenosine receptors are differentially expressed in different cell 
types in the body, with high levels of expression in the brain. Coupling to different G-
proteins and different affinities for adenosine also differentiate the actions of each receptor 
subtype. Of particular interest in the CNS are the A1 and A2A receptors, which have a 
multitude of regulatory roles that appear to be largely brain region-specific (Fredholm et al., 
2005). For example, in areas associated with learning and memory, adenosine has been 
implicated in the modulation of synaptic plasticity (de Mendonca and Ribeiro, 1996). Table 
1.2 outlines the four adenosine receptor subtypes, their affinity for adenosine, and their 
distribution in the brain.  
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Table 1.2. Adenosine receptor subtypes with their affinity for adenosine and expression 
distribution in the brain. Adapted from (Dunwiddie and Masino, 2001).  
Receptor 
Subtype 
Affinity for 
Adenosine   Distribution in the brain 
A1 ~70nM Most abundantly expressed throughout the brain 
A2A ~150nM Most abundant in striatum, olfactory tubercle, and nucleus 
accumbens 
A2B ~5100nM Expressed in small amounts in all brain areas 
A3 ~6500nM Expressed in the brain in significant amounts 
 
1.3.1 The adenosine A1 receptor 
The adenosine A1 receptor (A1R) is abundantly expressed in the brain (Latini et al., 
1996a; Ferré et al., 1997). A1Rs have been implicated in the inhibition of neuronal activity, 
shown to be coupled to reduced neurotransmitter release (Fredholm and Dunwiddie, 1988), 
activation of hyperpolarizing K+ currents (Trussell and Jackson, 1985), inhibition of Ca2+ 
currents (MacDonald et al., 1986), induction of intracellular protein kinase and phosphatase 
activity (Brust et al., 2006; Brust et al., 2007), and the reduction of excitatory AMPA 
receptor surface expression (Chen et al., 2014). Adenosine A1 receptor activity has been 
linked to inhibition of multiple neurotransmitter systems including glutamate, γ-aminobutyric 
acid (GABA), acetylcholine (Ach), norepinephrine (NE), serotonin (5-HT), and dopamine 
(DA) release (Fredholm and Dunwiddie, 1988; Dunwiddie and Masino, 2001). One of the 
most important neuromodulatory actions of the A1Rin the hippocampus is its inhibitory 
action on excitatory glutamatergic neurotransmission where synaptic activity can be almost 
entirely blocked when extracellular adenosine concentrations rise (Dunwiddie, 1980; Kocsis 
et al., 1984).  
1.3.2 The adenosine A2A receptor 
The excitatory adenosine A2A receptor is expressed to a lower degree compared to the 
A1R in most parts of the brain. However, in the striatum, olfactory tubercle, and nucleus 
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accumbens, A2ARs are highly expressed (Collis and Hourani, 1993). A2ARs generally have 
antagonizing actions to A1Rs, and are implicated in multiple mechanisms to increase 
neuronal activity (Costenla et al., 2011; Dias et al., 2012), for example, by activating 
Adenylyl cyclase, increasing cAMP and activating PKA, which has been shown to increase 
GluA1 AMPA receptor subunit activation (Dias et al., 2012). Activation of A2ARs has also 
been shown to increase presynaptic glutamate release (Rebola et al., 2008). An important 
attribute of the A2AR is that they have a lower affinity for adenosine than A1Rs, which is 
why the dominant actions of adenosine in the hippocampus are inhibitory (Alzheimer et al., 
1991a). Activation of A2ARs has been associated with the modulation of processes such as 
mood (Shen and Chen, 2009), learning and memory (Costenla et al., 2011), and 
neurodegeneration in stroke or hypoxia, as well as other neurodegenerative diseases (Cunha, 
2005; Pugliese et al., 2009). 
1.3.3 The adenosine A2B receptor 
The adenosine A2B receptor was first identified as a distinct adenosine receptor subtype 
following the observation that although it signals through the activation of adenylyl cyclase 
similar to the A2A receptor, it has a much lower affinity for adenosine and is widely 
expressed throughout the brain (Latini et al., 1996a; Dunwiddie and Masino, 2001). The A2B 
receptor, has been less well-characterized in the CNS compared to A1 and A2A receptors, 
with much of its physiological role unknown (Dunwiddie and Masino 2001). A notable 
action of A2B receptor activation in the hippocampus is positive modulation of Ca2+ levels 
and increases the activity of P-type Ca2+ currents in CA3 pyramidal neurons (Collis and 
Hourani, 1993; Feoktistov and Biaggioni, 1997). Although this is one of few roles known for 
A2B receptors, their low affinity for adenosine (See table 1.2) could indicate their activation 
occurs only when there is a drastic increase in adenosine tine, such as in pathological cell 
stress. Unfortunately, there is a current lack of an effective A2B receptor-specific 
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pharmacological agents which hinders an increased detailed understanding of this receptor 
subtype (Feoktistov & Biaggioni 1997). More work is required to further elucidate the 
physiological role of A2BRs in the CNS.  
1.3.4 The adenosine A3 receptor 
Finally, the adenosine A3 receptor is expressed in significant amounts throughout the 
brain (Zhou et al., 1992; De et al., 1993), although the A3R has the lowest affinity for 
adenosine compared to the other three receptor subtypes and therefore does not appear to 
significantly modulate synaptic function (Collis and Hourani, 1993). The highest amount of 
A3R mRNA is in the hippocampus and cerebellum (De et al., 1993), indicating higher 
receptor expression in these two important areas. A3R activation is associated with 
phospholipase C activation and increased inositol phosphate levels in the brain (Abbracchio 
et al., 1995). A3R activation using selective agonists reduces locomotor activity, suggesting a 
possible inhibitory role in the brain (Jacobson et al., 1993). A3Rs have been reported to act to 
uncouple A1Rs and metabotropic glutamate receptors (mGluRs) through a protein kinase C 
pathway (Dunwiddie et al 1997a, Macek et al 1998). This suggests a role for A3 receptors in 
the modulation of different G protein-coupled receptors.  
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Table 1.3. Summary of notable modulatory actions of adenosine receptor subtypes in 
the brain (Collis and Hourani, 1993; Dunwiddie and Masino, 2001; Chen et al., 2014). 
Receptor 
Subtype 
   Coupled  
   G-protein Actions in the brain 
A1 Gi and Go Inhibits neurotransmitter release 
  
Reduces AMPA receptor surface expression 
  
Activates K+ channels 
  
Inhibits Ca2+ channels 
A2A Gs and Golf Increases neurotransmitter release 
  
Increases Ca2+-permeable AMPA receptor 
expression 
  
Modulates locomotor activity 
A2B Gs Increases cAMP 
  
Potentiates P-type Ca2+ channels 
  
Increases excitatory release of aspartate 
A3 Gi and Gq Depress locomotor activity 
  
Causes A1R desensitization in the hippocampus 
 
Table 1.3 summarizes some of major known roles of the four adenosine receptor subtypes 
in the brain. Due to differential tissue and cell type expression of the four adenosine receptor 
subtypes and uniformity of each receptor subtype throughout the body, development of drugs 
that target adenosine receptors in specific tissues has been a major challenge for researchers 
(Dunwiddie and Masino, 2001). Although each receptor subtype differs in adenosine affinity, 
G-protein coupling, and signal transduction mechanisms (Shryock et al., 1998; Linden, 
2001), it is difficult to target adenosine receptors themselves as therapeutic targets. Instead, 
targeting intracellular adenosine receptor-mediated effects may prove effective in defining 
therapeutic targets for neuroprotection.  
 
1.4 Adenosine-mediated neuromodulation in the hippocampus 
In the hippocampus, adenosine has a dominantly inhibitory role due to the high levels of 
high-affinity A1 receptor expression (Ochiishi et al., 1999). Adenosine has been shown to 
modulate learning and memory functions including long-term potentiation (LTP) and long-
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term depression (LTD) (Alzheimer et al., 1991b; Zhang and Schmidt, 1998; de Mendonca 
and Ribeiro, 2001). A major mechanism by which adenosine modulates synaptic transmission 
in both physiological and pathophysiological conditions is through modulation of excitatory 
glutamatergic neurotransmission (Rebola et al., 2005). Glutamate is an extremely important 
excitatory neurotransmitter that induces synaptic transmission through its action on glutamate 
receptors, which are separated into two broad groups: metabotropic glutamate receptors 
(mGluRs) and ionotropic glutamate receptors. Ionotropic glutamate receptors include the 
ligand-gated AMPA, NMDA and kainate receptors (Nakanishi, 1992). AMPA receptors 
(AMPARs) mediate fast excitatory synaptic transmission, whereas NMDA receptors are 
known to mediate slower excitatory synaptic transmission (Lu et al., 1996).  
In ischemia, a major cause of neuronal death is through excess excitatory 
neurotransmission, known as excitotoxicity. Both NMDA and AMPA receptors are known to 
play a role in excitotoxicity in the hippocampus (Lu et al., 1996; Kristensen et al., 2001). 
NMDA receptors have been studied extensively as neuroprotective drug targets for ischemia, 
but unfortunately NMDA receptor antagonists were proven ineffective as neuroprotectants in 
clinical trials (Ikonomidou and Turski, 2002). Because of this, focus has shifted to AMPA 
receptors as potential drug targets.  
1.4.1 AMPA receptors 
AMPA receptors (AMPARs) are ligand-gated ion channels that mediate the majority of 
fast excitatory neurotransmission in the brain (Burnashev et al., 1992; Martin et al., 1993). 
Functional AMPARs form tetramers that form a ‘dimer-of-dimers’ of four subunits, GluA1-4 
(Nakagawa et al., 2005), forming Na+-, and sometimes Ca2+-selective ion channels 
(Burnashev et al., 1992). Each AMPAR subunit has three transmembrane domains (TM1,3,4) 
and one re-entrant loop (TM2) containing a glutamine/arginine (Q/R) editing site where 
glutamine is posttranslationally replaced with arginine in GluA2 subunits, which renders 
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them impermeable to Ca2+ (Martin et al., 1993; Gu et al., 1996). This is particularly important 
because AMPARs with GluA2 are Ca2+-impermeable, whereas GluA2-lacking AMPARs are 
permeable to Ca2+ (Burnashev et al., 1992; Greger et al., 2003).. Binding of glutamate to the 
extracellular ligand-binding site induces transient channel opening, inducing AMPAR-
mediated currents (Nakagawa et al., 2005). Tetrameric GluA2-containing AMPARs are most 
abundant in many cell types, with GluA2-lacking AMPARs, which are dominantly GluA1 
homomers and mediate transient increases in Ca2+ permeability, an essential function for 
example in LTP induction (Plant et al., 2006; Liu and Zukin, 2007).  
We recently showed that GluA1 and GluA2 subunit-containing AMPAR surface 
expression is significantly decreased in the hippocampus after adenosine A1 receptor 
activation with the agonist N6-cyclopentyladenosine (CPA) (Chen et al., 2014). Along with 
showing a physical and functional interaction between A1Rs with GluA1 and GluA2 
AMPAR subunits, we show that A1Rs induce endocytosis of these AMPAR subunits, which 
is differentially regulated by p38 mitogen-activated protein kinase (p38 MAPK), c-Jun N-
terminal kinase (JNK), protein phosphatase 2A (PP2A), and other potential intracellular 
second messenger proteins (Chen et al., 2014).  
1.4.2 Calcium-permeable AMPA receptors and GluA1 regulation 
Calcium permeability is a crucial attribute of GluA2-lacking AMPARs. Dysfunction in the 
regulation of AMPAR surface expression has been implicated in neurological diseases and 
neurodegeneration (Vandenberghe et al., 2000; Noh et al., 2005), and therefore, the tight 
regulation of AMPAR surface expression is essential. For example, in ischemic conditions 
with increased extracellular adenosine, calcium-permeable AMPARs (CP-AMPARs) have 
been shown to interact with adenosine A2ARs, whereby A2AR activation induces increased 
GluA1 surface expression through activating protein kinase A (PKA) (Dias et al., 2012). This 
A2AR-induced increased GluA1 surface expression has been associated with Ca2+-induced 
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excitotoxicity in hippocampal neurons (Noh et al., 2005). To modulate the trafficking and 
function of GluA1, there are multiple phosphorylation, palmitoylation, and ubiquitination 
sites present on intracellular GluA1 residues (Lee et al., 2010). This thesis explores two 
GluA1 phosphorylation sites, Ser831 and Ser845, with focus on protein phosphatase actions 
at these two serine residues. Table 1.4 outlines all currently known GluA1 phosphorylation 
sites and functions that they have been shown to modulate.  
 
Table 1.4. Currently known phosphorylation sites for GluA1. Data from (Roche et al., 
1996; Delgado et al., 2007; Clem and Huganir, 2010; Lee et al., 2010; Ai et al., 2011; Lu and 
Roche, 2012). 
Residue Kinase? Known Function 
Ser831 PKC/CaMKII modulates AMPAR currents 
  induction of LTP 
  controls single channel conductance 
Ser845 PKA modulates AMPAR excitation 
  critical for LTD expression 
  enhances mean open probability of GluA1 homomers 
Ser818 PKC 
promotes GluA1 synaptic incorporation 
Ser567 CaMKII negatively modulates Loop1-dependent AMPAR syanptic 
targeting 
Thr840 PKC reduced pT840 important in LTD 
 
 
PKA, a well-known serine/threonine protein kinase, phosphorylates GluA1 at a C-terminal 
serine residue, Ser845, which, among other things (Table 1.4), induces increased GluA1 
surface expression (Oh et al., 2006). Another serine residue, Ser831, a target of protein kinase 
C (PKC) and calcium/calmodulin protein kinase II (CaMKII), has also been shown to 
increase surface expression and single-channel conductance of the AMPAR channel (Barria 
et al., 1997). Internalization of GluA1 through an endocytic pathway has been shown to occur 
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by dephosphorylation of GluA1 at Ser845 (Ehlers, 2000). Thus, dynamic regulation of these 
two serine phosphorylation sites is a major mechanism of GluA1 regulation (Roche et al., 
1996), and therefore of the relative Ca2+ permeability at the synapse.  
 
1.5 Regulation of extracellular adenosine 
Extracellular concentrations of adenosine are tightly regulated, and changes in adenosine 
concentration can induce widespread effects. One mechanism through which adenosine is 
transported both directions across cell plasma membranes is through ENTs, which are widely 
expressed in the hippocampus (Baldwin et al., 2004). In ischemia/hypoxia, the concentration 
of extracellular adenosine increase dramatically up to 100 times normal levels (Dale et al., 
2000), with two possible sources: adenosine release from ischemic cells into the extracellular 
space, and extracellular ATP metabolism (Benarroch, 2008). As discussed above, this 
increased extracellular adenosine is dominantly inhibitory in the hippocampus (Yoon and 
Rothman, 1991).  
Two classes of nucleoside transporters exist in mammalian cells: concentrative nucleoside 
transporter (CNT) nucleoside pumps and equilibrative nucleoside transporters (ENTs) 
(Baldwin et al., 2004; Kong et al., 2004). ENTs are of particular interest due reports 
implicating ENT modulation as a contributing factor in ischemia/hypoxia-induced 
neurodegeneration (Ribeiro, 2005). ENTs are a subfamily of nucleoside transporters and are 
classified into four subtypes (ENT1-4), with ENT1 and ENT2 most widely expressed 
throughout the body including high levels of expression in pyramidal neurons in the 
hippocampus (Anderson et al., 1999). An important potential modulator of ENT1 expression 
and function is CK2, which targets two potential consensus sequences on the intracellular C-
terminal of ENT1 (Stolk et al., 2005; Bone et al., 2007). Phosphorylation of ENT1 increases 
its surface expression, which have been shown to be mediated by CK2 (Stolk et al., 2005). 
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This may have important implications during hypoxia/ischemia. Regulation of extracellular 
adenosine in ischemic or hypoxic conditions by ENTs is mediated by altering the surface 
expression of ENTs (Chu et al., 2013). It was shown by Zhang et al. (2011) that neuronal 
ENT1 reduced hypoxia/ischemia-induced increase extracellular adenosine and suggested 
ENT1 as a potential therapeutic target for neuroprotection (Zhang et al., 2011).  
 
1.6 Research objectives and Hypotheses 
The major objectives of this thesis are to investigate the role of protein phosphatases 
(PP1/PP2A/PP2B) and CK2 in A1R- and hypoxia-induced synaptic depression and/or 
neuronal damage. In neuronal insults, increased extracellular adenosine induces increased 
adenosine receptor activation (Dale et al., 2000). The dominantly expressed high-affinity A1 
receptor activation has been shown to induce significant synaptic depression through both 
presynaptic and postsynaptic modulatory mechanisms (Brust et al., 2006; Brust et al., 2007; 
Chen et al., 2014). Of particular importance, we recently showed that prolonged adenosine 
A1 receptor activation causes a phenomenon we termed APSD during A1R agonist drug 
washout. APSD was observed when fEPSPs in CA1 of rat hippocampal slices treated with 
CPA for 30min failed to recover to baseline levels even after 1 hour of agonist washout 
(Chen et al., 2014). This thesis aims to increase current understanding of the mechanism by 
which adenosine induces alterations in both AMPAR and ENT expression and function, and 
the implications of altered adenosine tone in the hippocampus caused by hypoxia and in 
small cortical PVD lesion in vivo. The following chapters show the results of the research 
that was carried out over the course of my Master’s degree research.  
The studies performed in Chapter 2 investigate a potential role for three major 
serine/threonine protein phosphatases in adenosine-mediated regulation of AMPAR surface 
expression: protein phosphatase 1 (PP1), protein phosphatase 2A (PP2A), and protein 
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phosphatase 2B (PP2B), also called calcineurin. All three phosphatases have been shown to 
mediate multiple functions in the brain such as LTP and LTD (Belmeguenai and Hansel, 
2005), different neuroprotective pathways (Don Yi and Simpkins, 2008; Hédou et al., 2008), 
and regulation of excitatory neurotransmission (Ito and Karachot, 1992; Launey et al., 2004). 
Results of these studies indicate a novel role for PP1, PP2A and PP2B in the regulation of 
A1R-induced synaptic depression in hypoxia via their dephosphorylation of GluA1 AMPAR 
subunits, which induce GluA1 endocytosis. After a 20 minute hypoxic insult. significant 
synaptic potentiation was induced by A2AR activation, which induces PKA-mediated GluA1 
phosphorylation, causing increased GluA1 surface expression (Dias et al., 2012). Using 
protein phosphatase inhibitor drug treatments, we showed that A1R-induced synaptic 
depression can be partially ameliorated by protein phosphatase inhibitor pre-treatments, and 
also shows that these drugs afford neuroprotection to hippocampal slices after prolonged 
hypoxia.  
Chapter 3 explores a functional interaction between ENT1, casein kinase 2 (CK2) and 
A1Rs in the functional consequences of modulating the function of these proteins in hypoxia. 
Inhibition of ENT1 and ENT2 induces increased extracellular adenosine tone, which was also 
shown after CK2 inhibition. This indicates that ENTs, of which ENT1 has CK2 target 
consensus amino acid sequences (Kiss et al., 2000; Handa et al., 2001), interact with CK2, 
which regulates ENT function in CA1 region of the rat hippocampus. When hippocampal 
slices were subjected to a 20min hypoxic insult, ENT1/2 inhibition prevented both hypoxia-
induced synaptic depression and normoxic reperfusion-induced synaptic potentiation. CK2 
inhibition also reduced hypoxia-induced synaptic depression and prevented reperfusion-
induced synaptic potentiation (APHP). Using 20min hypoxia, treatment of hippocampal 
slices with CK2 inhibitors proved to have neuroprotective abilities in hypoxia. Finally, 48 
hours after rats were given a permanent cortical ischemia pial vessel disruption (PVD) 
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surgery, hippocampal slices were shown to have increased inhibitory tone compared to sham-
operated animals. Overall, these studies implicate three major protein phosphatases, PP1, 
PP2A and PP2B, and CK2 in the regulation of adenosine-mediated reactions to hypoxic 
conditions in the hippocampus. Based on these data, we propose these essential proteins as 
neuroprotective targets in ischemic conditions in the brain.  
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Chapter 2: Adenosine-mediated regulation of GluA1-
containing AMPA receptors involves alterations of GluA1 
Ser831 and Ser845 phosphorylation: protein phosphatases 
1, 2A and 2B mediate adenosine A1 receptor-induced 
GluA1 endocytosis in rat hippocampal slices in 
hypoxia/reperfusion injury 
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2.1 Summary 
Synaptic remodeling is a major mechanism of autoregulation in the hippocampus during 
both physiological situations and neuronal insults such as hypoxia and ischemia. Adenosine 
contributes to the modulation of neuronal insult-induced changes in the hippocampus, acting 
through both the inhibitory A1 receptor and excitatory A2A receptor, with A1Rs having a 
higher affinity for adenosine than A2ARs (See Table 1.1). We recently showed a novel 
mechanism by which adenosine A1 receptor activation induces excitatory GluA1 and GluA2 
AMPA receptor subunit endocytosis and adenosine-induced persistent synaptic depression 
(APSD) in CA1 of rat hippocampal slices. The present study investigates the mechanism of 
adenosine-mediated GluA1 surface expression regulation by protein phosphatase 1 (PP1), 2A 
(PP2A), and 2B (PP2B). Using biotinylation Western blotting of hippocampal lysates and 
fEPSP electrophysiology experiments in CA1 of rat hippocampal slices, we show that A1R 
activation induces rapid GluA1 endocytosis and APSD, which was reduced by PP1, PP2A 
and PP2B inhibition. Additionally, the phosphorylation of two GluA1 serine residues, Ser831 
and Ser845, is reduced after prolonged A1 receptor activation. Inhibition of PP1/PP2A with 
okadaic acid (20nM), PP2A with fostriecin (20nM), PP1 with tautomycetin (20nM) and 
PP2B with FK506 (50nM), differentially prevented the reduction of phosphorylation at 
Ser831 and Ser845. In hypoxia/reperfusion experiments, adenosine induces rapid synaptic 
depression in CA1 followed by significant adenosine-induced post-hypoxic potentiation 
(APHP), which we found was induced by adenosine A2A receptor activation causing 
increased PKA activity, which increases GluA1 surface expression. A2AR inhibition with the 
selective antagonist SCH442416 (5nM) prevented the induction of APHP. Finally, 
hippocampal slices treated with protein phosphatase inhibitors followed by 20min hypoxia 
showed significantly less propidium iodide staining in the hippocampus compared to slices 
subjected to hypoxia alone, which was an indication of neurodegeneration induced by 
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hypoxia. This suggests a neuroprotective role for the inhibition of protein phosphatases in 
hypoxic conditions, revealing these as potential therapeutic targets. 
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2.2 Introduction 
Adenosine is an essential neuromodulator in the brain, and has been shown to play a role 
in a physiological processes including learning and memory (Hogan et al., 1998), and 
pathophysiological processes such as ischemic stroke (Rudolphi and Schubert, 1995) and 
Parkinson’s disease (Chen et al., 2001). Although adenosine’s role as an important 
neuromodulator has been established, the mechanism by which adenosine receptors modulate 
synaptic activity is less well understood. Of the four G-protein-coupled adenosine receptors 
(A1, A2A, A2B, and A3), the A1 and A2A receptors have the most pronounced and well-
classified expression in the central nervous system (CNS) and have opposing inhibitory and 
excitatory actions, respectively (Sichardt and Nieber, 2007). In hypoxia or ischemia, 
extracellular adenosine increases up to 100-fold from extracellular ATP breakdown and 
adenosine extrusion from ischemic cells (Dale et al., 2000; Pearson et al., 2001). In fact, 
peripheral plasma adenosine has been shown to be elevated in humans up to 15 days after a 
stroke or transient ischemic attack (Laghi Pasini et al., 2000), consistent with increased 
adenosine in the brain. Induction of synaptic depression by A1R activation is thought to 
afford neuroprotection to ischemic cells by preventing excitotoxicity by reducing glutamate 
signaling caused by increased glutamate release that can occur in hypoxia/ischemia (Liu et 
al., 2006). The role of adenosine in the induction of hippocampal synaptic depression in 
ischemia/hypoxia through adenosine A1 receptor (A1R) activation is thought to be 
neuroprotective by preventing excitotoxicity both presynaptically by inhibiting glutamate 
release (Obrietan et al., 1995) and postsynaptically by reducing cellular excitability (Cunha, 
2005). 
We recently showed that A1R activation induces rapid clathrin-mediated AMPAR 
endocytosis of excitatory glutamatergic AMPA receptors (AMPARs) through both a physical 
and functional interaction (Chen et al., 2014). Notably, A1Rs interact with GluA1 and GluA2 
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AMPAR subunits to induce AMPAR endocytosis mediated by p38 MAPK, JNK, and PP2A. 
We showed that p38 mitogen-activated protein kinase (MAPK) and c-Jun n-terminal kinase 
(JNK) inhibition prevented adenosine-induced GluA1- and GluA2-containing AMPAR 
internalization, although inhibition of p38 and JNK did not entirely prevent A1R-induced 
GluA1 internalization (Chen et al., 2014). We also showed that protein phosphatase 2A 
(PP2A) mediated adenosine-induced GluA2- and GluA1-containing AMPAR internalization 
where PP2A inhibition prevented A1R-induced AMPAR endocytosis. Additionally, 
prolonged A1R activation induced APSD in CA1 of rat hippocampus. In the current chapter, 
I further investigate the mechanism of A1R-induced AMPAR internalization, with specific 
focus on A1R-induced GluA1 subunit internalization.  
GluA1 is known to play an essential role in fast excitatory synaptic transmission in the 
hippocampus, and are essential for the induction of certain forms of synaptic plasticity (Lee 
et al., 2010). GluA1 is also present in a majority of hippocampal neurons (Rogers et al., 
1991). Of particular importance, AMPARs that lack the GluA2 subunit, the vast majority of 
those being GluA1 homotetramers, are permeable to Ca2+, and their overexpression has been 
shown to play a role in ischemia-induced neuronal death (Kwak and Weiss, 2006). 
Accordingly, blockade of Ca2+-permeable AMPARs (CP-AMPARs) has been shown to 
reduce cerebral ischemia-induced neuronal death (Noh et al., 2005). It follows that A1R-
induced GluA1 internalization is an endogenous protective mechanism to prevent acute 
excitotoxicity during neurotoxic stimuli such as in cerebral ischemia.  
GluA1 surface expression is known to be regulated in part by the phosphorylation state of 
two major C-terminal serine residues of GluA1, Ser831 and Ser845, which control multiple 
functions of GluA1 such as surface expression, synaptic translocation, channel open 
probability, and channel conductance (Lee et al., 2003). Phosphorylation of Ser831 and 
Ser845 by PKC/CaMKII and PKA, respectively, have been shown to induce increased GluA1 
 
 
23 
surface expression and synaptic localization (Gu et al., 1996; Esteban et al., 2003; He et al., 
2011). Dephosphorylation of Ser831 and Ser845 have also been shown to mediate a 
reduction in the surface expression of GluA1 (Beattie et al., 2000; Oh et al., 2006; Lee et al., 
2010). We previously showed that A1R activation induced reduced phospho-Ser831 
(pSer831) and pSer845 that accompanies A1R-induced GluA1 endocytosis (Chen et al., 
2014). We hypothesized that the reduction in GluA1 surface expression was due to PP2A 
activation, which I show here mediated A1R-induced GluA1 endocytosis. 
Due to the involvement of PP2A in A1R-induced GluA1 endocytosis (Chen et al., 2014), I 
examined an involvement of PP2A and other serine/threonine phosphatases in reducing the 
phosphorylation of Ser831 and Ser845. Three major serine/threonine phosphatases present in 
hippocampal neurons are protein phosphatase 1 (PP1), PP2A, and PP2B/calcineurin (Don Yi 
and Simpkins, 2008), all of which have increased activity in hypoxia and ischemia (Brust et 
al., 2006; Hédou et al., 2008; Shintani-Ishida and Yoshida, 2011). PP1, PP2A, and PP2B 
have been shown to play a role in different neuroprotective mechanisms and cellular 
responses to neuronal insult conditions, as well as AMPA and NMDA receptor modulation in 
the hippocampus (Beattie et al., 2000; Belmeguenai and Hansel, 2005; Don Yi and Simpkins, 
2008; Hédou et al., 2008). A1R stimulation induces multiple intracellular signals, including 
the recruitment of PP2A to the cellular membrane of hippocampal neurons (Brust et al., 
2006). We hypothesized that PP1, PP2A and PP2B activity mediates A1R-induced GluA1 
dephosphorylation, which contributes to A1R-induced GluA1 internalization.  
We tested this hypothesis using both fEPSP electrophysiology experiments and 
biotinylation Western blots of rat hippocampal slices with exposure to selective protein 
phosphatase inhibitors in the presence of N6-cyclopentyladenosine (CPA), a selective A1R 
agonist, and hypoxia/reperfusion conditions. We found that inhibition of PP1, PP2A, and 
PP2B reduced APSD in CA1 of rat hippocampal slices, and that PP1, PP2A, and PP2B 
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inhibiton specifically prevented GluA1 endocytosis after CPA treatment. Following a 20min 
hypoxic insult, there was reduced A1R surface expression and increased A2AR surface 
expression. After a 45min normoxic washout/reperfusion period, slices showed significantly 
increased GluA1, but not GluA2, surface expression, indicating increased Ca2+ permeable 
AMPA receptors (CP-AMPARs), which increase neuronal excitability (Liu and Zukin, 
2007).. In CA1, hypoxia induced rapid synaptic depression whereas normoxic reperfusion 
induced significant synaptic potentiation, which was subsequently shown to involve A2AR 
activation. Treatment with protein phosphatase inhibitors also reduced hypoxia-induced 
hippocampal neuronal death, indicating that these may be therapeutic targets to reduce 
hypoxia-induced neuronal death. The results presented below indicate an important role for 
protein phosphatases in the acute neuronal response to hypoxic insult conditions in the 
vulnerable tissue of the hippocampus.  
 
2.3 Methods 
2.3.1 Ethics Statement 
All animals were treated according to guidelines of the Canadian Council for Animal Care 
(CCAC) under the supervision of the University of Saskatchewan Committee on Animal 
Care and Supply under animal protocol approval number 20070090. 
2.3.2 Hippocampal Slice Preparation 
Young male Sprague Dawley rats (pn18-30 days) were anaesthetized with halothane and 
rapidly decapitated, with the brains immediately excised and submerged in oxygenated, ice-
cold high-sucrose dissection medium containing the following: 87mM NaCl, 25mM 
NaHCO3, 25mM glucose, 75mM sucrose, 2.5mM KCl, 1.25mM NaH2PO4, 7.0mM MgCl2, 
and 500µM CaCl2 (Brust et al., 2007). Hippocampal slices were taken at 400µm thickness 
using a vibrating tissue slicer (VTS1200S, Vibram Instruments, Germany), and slicing was 
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performed in the same ice-cold oxygenated dissection medium as above. Slices were 
maintained for at least 1h at room temperature in oxygenated artificial cerebrospinal fluid 
(aCSF) containing the following: 126mM NaCl, 2.5mM KCl, 2.0mM MgCl2, 1.25mM 
NaH2PO4, 26mM NaHCO3, 10mM glucose, 2.0mM CaCl2 (Brust et al., 2007). Oxygenation 
was accomplished by continually bubbling the solution with 95% O2/5% CO2.  
2.3.3 Drug Treatments 
Hippocampal slices were incubated in one of the following treatments: dimethyl sulfoxide 
(DMSO, vehicle control, Sigma, St. Louis, MO), fostriecin (20nM, Tocris, Bristol, UK), 
okadaic acid (3nM, 20nM, Tocris), tautomycetin (20nM, Tocris), and FK506 (50nM, Sigma). 
Fostriecin is a selective PP2A inhibitor, okadaic acid at the concentration used inhibits both 
PP1 and PP2A, tautomycetin is a selective PP1 inhibitor, and FK506 is a selective PP2B (also 
called calcineurin) inhibitor. N6-cyclopentyladenosine (CPA) was used as a selective 
adenosine A1R agonist at 500nM, and SCH442416 (Sigma) was used as a selective 
adenosine A2A receptor antagonist at 5nM. All drugs were dissolved in DMSO (Sigma) 
before being added to aCSF. The final concentration of DMSO was < 0.1% in each treatment. 
2.3.4 Electrophysiology 
Hippocampal slices were submerged in an electrophysiology recording chamber with 
constant perfusion of oxygenated aCSF (3ml/min) containing the same concentration of drug 
treatment as was used in drug pre-incubation. Field excitatory postsynaptic potentials 
(fEPSPs) were evoked by orthodromic stimulation of the Schaffer collateral pathway using a 
bipolar tungsten stimulating electrode (Axon Instruments, Foster City, CA). A pulled glass 
recording microelectrode filled with aCSF (resistance 1-3MΩ) was placed in CA1 stratum 
radiatum, which recorded fEPSPs induced by Schaffer collateral stimulation. Two different 
experimental protocols were used throughout the course of this research. In both protocols, 
fEPSPs were evoked for 0.1ms every 30s throughout each experiment. Slices were constantly 
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perfused with aCSF containing the appropriate protein phosphatase inhibitor drug treatments 
and concentration listed above. Baseline recordings were set to approximately 60% of 
maximal fEPSP values.  
The first protocol was performed by recording a stable baseline recording of at least 20min 
followed by 30min perfusion of CPA (500nM) and a 60min washout period. The second 
protocol was performed with a 20min stable baseline recording followed by 20min hypoxia 
and 45min normoxic reperfusion. Hypoxia was achieved by bubbling aCSF with 95% 
N2/5%CO2 for at least 20min prior to the experiment and continually over the course of the 
experiment. The fEPSP signals were amplified 1000 times with an AC amplifier, band-pass 
filtered at 0.1-100Hz, digitized at 10kHz using a Digidata 1440A digitizer (Axon 
Instruments), and saved to a computer as a Clampex 9.0 (Axon Instruments) file. The 
collected fEPSP data were analyzed using Clampfit 9.0 (Axon Instruments). fEPSP slopes 
were normalized to the mean of the 10 sweeps (5min) immediately preceding drug perfusion. 
The mean normalized fEPSP slope was plotted as a function of time with error bars 
representing the standard error of the mean (SEM). Sample traces are the average of 5 sweeps 
from a representative recording from each treatment group. All histograms show the mean 
normalized percent inhibition from baseline ± SEM. Statistical significance was assessed 
using one-way analysis of variance (ANOVA) with Tukey-Kramer post-hoc test. 
2.3.5 Biochemistry 
For biochemistry studies, one rat was used for each different treatment group in every 
experiment, with each brain’s hippocampal slices distributed equally between treatment 
groups A minimum of three of these experiments was performed prior to analysis. Following 
appropriate drug incubation in protein phosphatase inhibitors or DMSO (vehicle control), 
brain slices were treated with CPA (500nM) for 30min or hypoxia for 20min. CPA-treated 
slices were rapidly cooled to 4°C, and hypoxia-treated slices were either immediately cooled 
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or incubated in normoxic aCSF washout for 45min and then cooled to 4°C. To isolate cell 
surface proteins, slices were treated with NHS-SS-Biotin (1mg/ml, Thermo Scientific) for 1h 
at 4°C. The biotin reaction was quenched with glycine buffer containing 192mM Glycine and 
25mM Tris (pH 8.3). Slices were then transferred to homogenization tubes and homogenized 
in lysis buffer (pH 8.0) containing 50mM Tris, 150mM NaCl, 1mM EDTA, 1mM NaF; and 
the following protease inhibitors: 1mM PMSF, 10g/L aprotinin, 10g/mL pepstatin A, 10g/mL 
leupeptin, 2mM Na3VO4, 20mM sodium pyrophosphate, 3mM benzamidine hydrochloride, 
and 4mM glycerol 2-phosphate with 1% NP-40 detergent.  
A Bradford Assay was performed with DC Protein assay dye (Bio-Rad) to determine 
protein concentration in the lysates, and 500µg of protein lysate diluted in lysis buffer was 
loaded into Streptavidin agarose beads (Thermo Scientific) and rotated overnight at 4°C. The 
beads were then washed 4-6 times the next day with lysis buffer containing 0.1% NP-40 
(otherwise same as above). The proteins were eluted by adding 50µl of 2X Laemmli sample 
buffer (Bio-Rad) and boiling the samples at 95 °C for 5min. Whole cell lysate samples of 
50µg were eluted in 20µl of the same Laemmli buffer and boiled for 5min. Samples were 
loaded into 10% SDS-PAGE gels and run for 1h. Proteins were transferred from gels to 
Immobilon-PSQ transfer membranes (Millipore, 3h at 4°C). Membranes were then treated 
with primary antibodies overnight at 4°C as follows: GluA1 (Ms mAb, Millipore), GluA1-
pSer831 (Millipore), GluA1-pSer845 (Millipore), GluA2 (Millipore), A1R (Millipore), and 
A2AR (Millipore). Membranes were then probed with appropriate secondary antibody and 
then ECL was performed (Santa-Cruz). Analysis was performed using Quantity One Basic 
(BioRad) and ImageJ (NIH, public domain). Graphs were constructed using GraphPad Prism 
6.0 (GraphPad). Data are presented as mean ± SEM. Statistical significance was assessed 
using a one-way ANOVA test and a Tukey-Kramer multiple comparison test using GraphPad 
InStat version 3.0 (GraphPad). 
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2.3.6 Propidium Iodide Staining 
Propidium iodide (PI) is an effective fluorescent marker for cell death due to the fact that 
it only enters and labels cells with disrupted plasma membranes. It produces strong red 
fluorescence when excited by green light. Propidium iodide staining and subsequent confocal 
imaging of rat hippocampal slices were used to examine the effect of protein phosphatase 
inhibitor treatments on cell survival after a 20min hypoxic insult. The methods used were 
adapted from Pugliese et al. (2009).  
Following equilibration of hippocampal slices for 1h after slicing, the following drug 
treatments were added: okadaic acid (20nM), fostriecin (20nM), tautomycetin (20nM), and 
FK506 (50nM). Slices were incubated in these treatments for 1h and were then subjected to a 
20min hypoxic insult by replacing oxygenated aCSF with hypoxic aCSF that was bubbled 
with 95%N2/5%CO2 prior to, and continuously throughout the hypoxic insult. After 20min 
hypoxia, aCSF was replaced with normoxic aCSF and the slices were incubated at room 
temperature for 3h. During the final 1h incubation period, 5µg/ml propidium iodide (Sigma) 
was added to the aCSF. Following the incubation period, slices were rinsed thoroughly in 
aCSF and then fixed in 4% paraformaldehyde at 4°C overnight. The following day, slices 
were washed 3 x 15min in 1X PBS and then mounted on glass microscope slides (VWR) and 
sealed using Prolong Gold Antifade Reagent (Invitrogen). After the addition of PI, all 
subsequent procedures were performed in the dark to prevent photobleaching.  
Hippocampal slices were imaged using a Zeiss LSM700 laser scanning confocal 
microscope (Carl Zeiss, Germany) using green light (543nm) to induce PI fluorescence. The 
whole hippocampus was imaged in pieces using a 10x objective lens, and images of CA1 
pyramidal neurons were obtained using the Zeiss Plan-Apochromat 63x/1.6 oil objective lens 
(Carl Zeiss). CA1 images were acquired as Z-stack images of 200µm depth into the 
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hippocampal slice with each Z-stack image taken at 2µm. Two Z-stack images were taken 
along CA1 for each slice and were averaged using densitometry analysis.  
Data was collected using Zeiss Zen 2009 version 5.5 software (Carl Zeiss) and was 
analyzed using ImageJ. Z-stack images closest to the outer top and bottom of the 
hippocampal slices were not analyzed, as the neuronal damage in those areas was enhanced 
by the slicing procedure. The inner-most 20µm (~100µm into the slice) segments were 
combined as maximum intensity projections and intensities were compared between 
treatment groups using densitometry analysis. Collected densitomtry data was normalized to 
time control slices that were treated along with each experiment. Data was graphed as a 
percentage of the time control value and analyzed for significance against this control value 
(100%). Full hippocampal images were assembled as montages of the entire hippocampal 
slice using Adobe Photoshop CS6 (Adobe Systems, Mountain View, CA).  
 
2.4 Results 
2.4.1 Inhibition of PP1, PP2A and PP2B prevented CPA-induced GluA1 internalization, 
whereas only PP2A inhibition prevented GluA2 internalization.  
We first sought to test the effect of A1R activation in hippocampal slices that were pre-
incubated in PP1, PP2A, and PP2B inhibitors for 1h followed by a 30min treatment with the 
A1R agonist CPA (500nM). We previously showed that the PP2A inhibitors okadaic acid 
(20nM) and fostriecin (20nM) prevented A1R-induced GluA1 and GluA2 internalization 
(Chen et al., 2014). In this experiment, we used both okadaic acid and fostriecin at the same 
concentrations used previously, and also used the PP1-selective inhibitor tautomycetin 
(20nM) and the PP2B-selective inhibitor FK506 (50nM). Following a 30min treatment with 
500nM CPA, slices were biotinylated and examined for AMPAR surface expression. 
Resultant Western blots show that hippocampal slices that were treated with tautomycetin, 
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okadaic acid, fostriecin, and FK506 prevented the CPA-induced reduction in GluA1 surface 
expression (Figure 2.1A,B). Compared to CPA, which induced approximately 40% reduction 
in surface GluA1, phosphatase inhibitor treatments did not significantly alter GluA1 surface 
expression compared to control (100%). Conversely, CPA-induced GluA2 internalization 
was prevented by okadaic acid and fostriecin, but not tautomycetin or FK506 (Figure 
2.1C,D). Since the concentration of okadaic acid used may be selective for both PP2A and 
PP1, the effect of okadaic acid was compared to the effect of either fostriecin or 
tautomycetin, which shows that the effect of okadaic acid on GluA2 internalization is likely 
due to PP2A alone. Additionally, PP2A has a higher affinity for okadaic acid compared to 
PP1 (Bialojan and Takai, 1988). These data indicate that PP2A is involved in A1R-induced 
GluA1 and GluA2 internalization, whereas PP1 and PP2B are involved in GluA1 
internalization but not GluA2 internalization after A1R activation.  
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Figure 2.1. Protein phosphatase inhibitors reduced CPA-induced GluA1 internalization, 
and PP2A inhibition reduced CPA-induced GluA2 internalization. Biotinylated Western 
blots of hippocampal slices exposed to 30min CPA treatment (500nM) with pre-incubation in 
okadaic acid (20nM), fostriecin (20nM), tautomycetin (20nM), and FK506 (50nM). (A) 
Representative Western blots showing that GluA1 surface expression was reduced by 
approximately 40% after CPA treatment with no other drugs added, and treatment with 
protein phosphatase inhibitors for 1h prior to CPA treatment significantly reduced CPA-
induced GluA1 internalization. Whole lysates probed for GluA1 showed constant levels 
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across all treatments, indicating that there is no significant intracellular degradation of GluA1 
during CPA treatment. (B) Summary bar graph of results in A showing the percentage of 
control (100%) of the surface expression of GluA1. (C) Blots probed for GluA2 expression 
showed that CPA treatment reduced GluA2 surface expression in surface biotinylated blots. 
Treatment with okadaic acid and fostriecin, PP2A inhibitors, prevented CPA-induced GluA2 
internalization, with fostriecin significantly preventing GluA2 internalization compared to 
DMSO. Treatment with tautomycetin and FK506 did not prevent GluA2 internalization, 
indicating that PP1 and PP2B do not play a role in GluA2 surface regulation. Whole lysate 
levels of GluA2 did not significantly change between treatment groups, indicating there was 
no intracellular GluA2 degradation. (D) Summary bar chart for GluA2 expression from blots 
in C. Blots were normalized to intracellular GAPDH. Graphed values are shown as mean ± 
SEM, n=4-6 independent experiments, * P<0.05, ** P<0.01 and *** P<0.005. 
 
2.4.2 Protein phosphatases 1, 2A, and 2B are involved in GluA1 phosphorylation at Ser831 
and Ser845. 
It has been shown that two C-terminus serine residues of GluA1, Ser831 and Ser845, are 
essential regulatory phosphorylation sites for GluA1 trafficking and function (Oh and 
Derkach, 2005). We recently showed that Ser831 and Ser845 phosphorylation was decreased 
after treatment with a relatively large dose of CPA (500nM) (Chen et al., 2014). To examine 
the role of PP1, PP2A and PP2B in A1R-mediated GluA1 dephosphorylation at Ser831 and 
Ser845, we tested the hypothesis that the phosphorylation state of Ser831 and Ser845 is 
modified by protein phosphatase inhibitor pre-incubation (1h, same concentrations as above) 
followed by 30min CPA treatment with protein phosphatase inhibitor pre-treatment (1h). 
Western blots probed for phosphorylated GluA1 at either Ser831 or Ser845 (pSer831 and 
pSer845) show that whole-cell levels of pSer831 and pSer845 were significantly reduced 
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after CPA treatment, by 25% and 35%, respectively (Figure 2.2A,B), which corresponds to 
the reduced GluA1 surface expression shown prior (Figure 2.1).  
Hippocampal slices were treated with okadaic acid (20nM), fostriecin (20nM), 
tautomycetin (20nM) and FK506 (50nM) for one hour prior to administration of CPA 
(500nM) for 30 minutes. Figure 2.2 shows representative Western blots probed for whole 
lysate levels of pSer831 and pSer845, which were normalized to whole cell levels of GluA1. 
The level of pSer831 was significantly reduced following CPA treatment alone, and the 
reduction of pSer831 was prevented by tautomycetin (20nM) and FK506 (50nM) (Figure 
2.2A), whereas okadaic acid and fostriecin did not significantly prevent the CPA-induced 
reduction of pSer831. CPA-induced reduction of Ser845, on the other hand, was prevented by 
okadaic acid and fostriecin whereas tautomycetin and FK506 did not significantly increase 
pSer845 compared to vehicle control (DMSO + CPA). These results indicate that Ser831, a 
PKC/CaMKII phosphorylation target (Roche et al., 1996), may be preferentially 
dephosphorylated by PP1 and PP2B whereas Ser845, a PKA target, could be preferentially 
targeted by PP2A. Taken together, these results reveal a differential regulation of Ser831 and 
Ser845 phosphorylation by these three phosphatases, which corresponds to CPA-induced 
GluA1 endocytosis (Figure 2.1).  
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Figure 2.2. Dephosphorylation of GluA1 at Ser831 and Ser845 is mediated by A1R-
induced protein phosphatases 1, 2A and 2B activity. Western blots of hippocampal lysates 
treated with protein phosphatase inhibitors. (A) left: Representative whole lysate blots of 
hippocampal lysates treated with okadaic acid (20nM), fostriecin (20nM), tautomycetin 
(20nM), or FK506 (50nM) for 1h prior to additional 30min CPA treatment. Phosphorylated 
Ser831 (pSer831) of GluA1 was reduced after CPA treatment, and tautomycetin significantly 
reduced this effect. GluA1 expression was not significantly different between treatments, 
indicating no reduction in whole cell GluA1 levels.. right: Summary bar graph of results for 
pSer831 levels in right blot. (B) left: Representative blots showing that CPA treatment also 
significantly reduced levels of GluA1-pSer845, which was prevented by okadaic acid and 
fostriecin treatment. Tautomycetin and FK506 did not prevent this CPA-induced reduction in 
pSer845. right: summary bar graphs show that pSer845 was significantly reduced by CPA 
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treatment alone, with tautomycetin, and with FK506, but not with okadaic acid and fostriecin, 
indicating that PP2A mediates CPA-induced reduction of pSer845. N=3 independent 
blots/experiments. Average values are mean ± SEM, Significance values: * P<0.05, ** 
P<0.01 and *** P<0.005. 
 
2.4.3 Synaptic depression and APSD in area CA1 are reduced by protein phosphatase 
inhibition. 
To examine the hypothesis that protein phosphatase inhibition prevents CPA-induced 
synaptic depression and reduced APSD, described previously (Chen et al., 2014), we 
performed fEPSP recordings in rat hippocampal slices. CA1 region fEPSP recordings were 
evoked from hippocampal slices pre-treated with protein phosphatase inhibitors (see above) 
for a minimum of 1h prior to recording. APSD was induced using a 30min CPA treatment 
(500nM) followed by a 1h washout period. Control (DMSO) slices showed significant 
synaptic depression (~80%, n=10 slices, all from different rats) with CPA treatment, which 
did not recover to baseline levels during washout, indicating APSD (Figure 2.3A,B). 
Hippocampal slices that were treated with the protein phosphatase inhibitors okadaic acid 
(20nM, n=8), fostriecin (20nM, n=9), tautomycetin (20nM, n=7) and FK506 (50nM, n=9) 
showed reduced synaptic depression during CPA treatment, accompanied by reduced APSD 
in washout (Figure 2.3).  
Synaptic depression after CPA treatment (Figure 2.3B,C) was significantly reduced by 
pre-treatment with the protein phosphatase inhibitors, with okadaic acid most able to prevent 
synaptic depression and FK506 preventing the least synaptic depression. During washout, the 
amount of fEPSP recovery was compared between treatment groups. Compared to control 
(DMSO), okadaic acid, fostriecin, FK506, and tautomycetin improved the amount of fEPSP 
recovery in washout (Figure 2.3D), with each recovering by about 30% during the 1h 
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washout period, similarly to control. Although there was less synaptic depression and APSD 
in slices treated with phosphatase inhibitors, APSD was still observed in protein phosphatase 
inhibitor-treated slices, indicating that protein phosphatases, although important, are not the 
only proteins involved in APSD.  
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Figure 2.3 Synaptic depression in area CA1 is reduced by protein phosphatase 1, 2A, 
and 2B inhibition. (A) Representative fEPSP traces for each treatment showing a sample 
trace at the end (final 5min) of the 20min baseline recording (1), at the end of 30min CPA 
treatment (2), at the end of 1h washout period (3), and an overlay of the three representative 
traces (1+2+3). Each representative trace is an average of the final 10 sweeps (5min) of each 
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of the three parts of the experiment (baseline, CPA, and washout). All recordings were 
normalized to their own baseline value (100%). (B) Time-course plot of average fEPSP 
slopes normalized to baseline (100%). (C) Summary bar graph showing fEPSPs as a 
percentage of the baseline recording level at the end of a 30min CPA treatment. Hippocampal 
slices treated with CPA and no drug inhibitors (DMSO) showed approximately 75% synaptic 
depression. Okadaic acid, fostriecin, tautomycetin, and FK506 incubation for 1h prior to the 
experiment significantly reduced the amount of synaptic depression caused by CPA. (D) 
Summary bar graph of the mean fEPSP slope at the end of the 1h washout period. DMSO 
slices recovered by about 20%, with fEPSPs recovering to about 50% of baseline. On the 
other hand, the fEPSP slopes for slices treated with protein phonsphatase inhibitors was 
significantly higher at the end of the washout period. n=7-10 slices were recorded for each 
treatment group from different rats. Graphed values are shown as mean ± SEM. Significance 
values: *= p<0.05, **= p<0.01, ***= p<0.001.  
 
2.4.4 Protein phosphatase inhibitor treatment before hypoxia altered synaptic depression 
during hypoxia and post-hypoxic potentiation in normoxic washout 
To test the functional involvement of PP1, PP2A and PP2B in hypoxia-induced synaptic 
depression and subsequent synaptic recovery during reperfusion, we subjected hippocampal 
slices pre-treated with okadaic acid, fostriecin, tautomycetin or FK506 (same concentrations 
as above) to a 20min hypoxic insult followed by a 45min normoxic reperfusion. Hypoxia was 
induced by bubbling aCSF with 95%N2/5%CO2 for a minimum of 20min prior to the start of 
the experiment. This experimental protocol was used to mimic an ischemia/reperfusion (I/R) 
injury, and to examine the role of protein phosphatases in mediating the cellular response to 
I/R injury. Hypoxic insult induced rapid synaptic depression in all hippocampal slices, with 
no significant difference between control and okadaic acid, fostriecin, tautomycetin, or 
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FK506 treated slices (Figure 2.4B,C). In normoxic washout, control (DMSO) slices 
recovered to baseline quickly and then continued to potentiate to levels approximately 160% 
of baseline (Figure 2.4B,D). This post-hypoxic potentiation was seen to differing degrees in 
the protein phosphatase inhibitor-treated slices, only FK506-treated slices significantly 
reduced post-hypoxia potentiation much closer to baseline levels (~110%). These results 
indicate that A1R-mediated protein phosphatase activation is only one of many cellular 
response mechanisms that are activated in hypoxia. In normoxic reperfusion, post-hypoxia 
potentiation occurred, which was significantly reduced by FK506 treatment, indicating a 
differential role for these phosphatases during hypoxia/reperfusion injury.  
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Figure 2.4 Protein phosphatase inhibitor treatment did not significantly alter hypoxia-
induced synaptic depression, but FK506 prevented post-hypoxia potentiation in 
normoxic reperfusion. (A) Representative fEPSP traces shown as an average of the final 10 
traces (5min) of each treatment period: 1. baseline recording, 2. hypoxia, 3. normoxic 
reperfusion, and 1+2+3 shows an overlay of the three representative traces. (B) Time-course 
plot of fEPSP experimental data showing mean fEPSP slopes for each recording plotted as a 
percentage of baseline values (100%), with each trace showing the average of normalized 
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fEPSP data for each independent n value. (C) Summary bar graph showing average fEPSP 
data for the final 10 sweeps (5min) of hypoxia. Compared to control, there were no 
significant changes in fEPSP slope, but tautomycetin (20nM) and okadaic acid (20nM) 
treatment showed significantly less synaptic depression than fostriecin (20nM) and FK506 
(50nM) treatment. (D) Summary bar graph showing the final 5min of a 45min normoxic 
washout period. Control (DMSO) slices showed significant synaptic potentiation following 
hypoxia, with slices potentiating to about 160% of baseline (100%). FK506 treatment 
significantly reduced this post-hypoxia potentiation, with slices potentiating to only about 
135% of baseline values. N = 7-9 separate experiments for each treatment. Data is shown as 
mean ± SEM. Significance values: * = p<0.05, ** = p<0.01. 
 
2.4.5 Post-hypoxia reperfusion increased surface GluA1, but not GluA2, which is removed 
after A2A receptor inhibition. 
We previously showed that a 20min hypoxic insult to hippocampal slices induces reduced 
AMPAR and A1R surface expression, and increases A2AR surface expression (Chen et al., 
2014). We hypothesized that following hypoxia, A1R internalization corresponds to A1R 
desensitization, and that excitatory A2AR activation was contributing to the post-hypoxic 
potentiation seen during normoxic washout in the above fEPSP experiment (Figure 2.4). 
Following 20min of hypoxia, both GluA1 and GluA2 surface expression is significantly 
reduced compared to control (Figure 2.5A). Whole cell levels of GluA1 and GluA2 did not 
change, indicating that there is no significant AMPAR degradation inside the cell.  
To test whether A2ARs induce increased AMPAR surface expression during normoxic 
washout, hippocampal slices were treated with SCH442416 (5nM) to inhibit A2AR 
activation 1h prior to inducing hypoxic insult. Slices were then subjected to 20min hypoxia 
followed by 45min normoxia and then immediately biotinylated. Western blot data from 
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these experiments show that after the 45min normoxic washout period, GluA1 surface 
expression, but not GluA2 expression, was significantly increased compared to control 
(Figure 2.5D-F). Treatment with SCH442416 prevented increased GluA1 surface expression, 
indicating that A2ARs induce the increased GluA1 surface expression seen in hypoxia 
alone(Figure 2.5D,E, middle lane). Normoxic washout did not increase GluA2 surface 
expression after hypoxia, and SCH442416 did not alter surface levels of GluA2 compared to 
hypoxia and subsequent normoxia alone (Figure 2.5D,F), indicating that A2ARs did not 
induce increased GluA2 surface levels in post-hypoxic conditions. Taken together, these data 
indicate differential regulation of GluA1 and GluA2 surface expression after a hypoxic insult, 
with A2AR activation during normoxic washout inducing increased GluA1, but not GluA2 
surface expression.  
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Figure 2.5 Hypoxia induced GluA1 and GluA2 internalization, whereas after normoxic 
washout, A2ARs induce increased GluA1, but not GluA2, surface expression. (A) 
Representative biotinylated Western blots of hippocampal slices subjected to 20min hypoxia 
and then immediately biotinylated. Both GluA1 and GluA2 surface expression was decreased 
after hypoxia. (B) Summary bar graph of GluA1 surface expression with and without hypoxia 
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shown in A (top two blots). Hypoxia induces significantly reduced GluA1 surface expression 
compared to control. (C) Summary bar graph showing surface GluA2 levels with and without 
a 20min hypoxic insult showing reduced surface GluA2 after hypoxia. (D) Representative 
blots showing surface expression of GluA1 and GluA2 in hippocampal slices subjected to 
20min hypoxia followed by 45min normoxic washout. Blots show increased GluA1 after the 
washout period which was prevented with the treatment of SCH442416 (5nM), an A2AR-
selective inhibitor. GluA2 levels were reduced after the normoxic washout with or without 
SCH442416 treatment. (E) Summary bar graph of surface GluA1 expression after normoxic 
washout. GluA1 levels were significantly increased after normoxia, and this increase was 
prevented by SCH442416, with GluA1 surface levels comparable to control slices. (F) 
Summary bar graph showing surface GluA2 levels. SCH442416 did not alter the hypoxia-
normoxic washout decrease in surface GluA2. N=3 independent blots with at least 2 rats per 
experiment. Values are shown as mean ± SEM. Significance values: *= p<0.05, **= p<0.01. 
Figure 2.5 A, B, and C were gathered with the help of Zhicheng Chen, who performed 
Western blot experiments in these figures.  
 
2.4.6 Following normoxic washout after hypoxia, there is increased pSer831 and pSer845 
in hippocampal slices compared to time control, and A2AR inhibition prevented hypoxia-
reperfusion-induced increase in pSer831 and pSer845.  
A2ARs are known to induce increased PKA activity, which is known to phosphorylate 
GluA1 at Ser845 and increase GluA1 surface expression (Dias et al., 2012). We hypothesized 
that A2AR blockade prior to 20min hypoxia and 45min normoxic washout would prevent 
increased GluA1 phosphorylation. After the 45min washout period, both pSer831 and 
pSer845 increased in biotinylated and whole lysate blots (Figure 2.6). Blots for pSer831 show 
that hypoxia followed by normoxic washout induced significantly increased pSer831 to about 
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140% of baseline levels (Figure 2.6A,B). Pre-incubation of slices with SCH42416 (5nM, 
A2AR antagonist) reduced the increase of pSer831 to about 120% of baseline, which was not 
significantly different from control or hypoxia alone, but reduced compared to hypoxia alone. 
Levels of pSer845 was significantly increased to about 120% above control after normoxic 
washout, which was prevented with SCH442416 treatment, where pSer845 levels returned to 
control levels (Figure 2.6C,D). These results indicate that A2ARs are involved in hypoxic 
reperfusion-induced phosphorylation of GluA1 at Ser831 and Ser845, which corresponds to 
increased A2AR-mediated GluA1 surface expression (Figure 2.5).  
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Figure 2.6 After hypoxia and normoxic washout of hippocampal slices, pSer831 and 
pSer845 are increased, and SCH442416 prevented this increase. (A) Representative blots 
showing that compared to time-control slices (DMSO, far left lane), treatment with 20min 
hypoxia followed by 45min normoxic reperfusion caused significantly increased levels of 
cellular pSer831 (DMSO, center lane). Slices that were treated with SCH442416 (5nM) 1h 
prior to the hypoxia-reperfusion experiment (right lane) prevented the hypoxia-reperfusion-
induced increase in pSer831. (B) Summary bar graph showing average data for blots shown 
in A. Hypoxia-reperfusion induced significantly increased pSer831 compared to time-control 
(100%). Slices treated with SCH442415 before hypoxia-reperfusion showed increased 
pSer831 levels compared to control, but not significantly (i.e. P>0.05). (C) Representative 
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blots of a membrane used for experiment in A that were stripped and re-probed for pSer845 
levels. Hypoxia-reperfusion-treated slices showed significantly higher pSer845 levels 
compared to time control, and SCH442416-treated slices showed no increase in pSer845 
levels after hypoxia and reperfusion alone. (D) Summary bar graph showing average data 
from all blots analyzed for this experiment. Graphed values are shown as mean ± SEM, with 
n=4 independent experiments performed. Significance values: *= p<0.05, **= p<0.01, ***= 
p<0.005.  
 
2.4.7 Hippocampal slices treated with SCH442416 with or without protein phosphatase 
inhibitors prevented the induction of post-hypoxia potentiation. 
Following the discovery that A2ARs mediate post-hypoxic increases in surface GluA1 and 
pSer831/pSer845 (Figure 2.5, 2.6), we performed fEPSP experiments to test whether 
SCH442416 (5nM) treatment prevents adenosine-induced post-hypoxic potentiation, and 
whether A2AR blockade modulates post-hypoxia potentiation during normoxic washout. In 
hypoxia, there were no significant differences in hypoxia-induced synaptic depression 
between treatment groups, consistent with the previously shown increase in extracellular 
adenosine in hypoxia (Dale et al., 2000) (Figure 2.7C). Following 20min hypoxia, slices were 
then reperfused with normoxic solution for 45min. At the end of the washout period, control 
slices showed significant (~160%) fEPSP potentiation. On the other hand, slices that were 
preincubated in SCH442416 alone or with okadaic acid (20nM), fostriecin (20nM), 
tautomycetin (20nM) or FK506 (50nM) showed that SCH442416 prevented post-hypoxia 
potentiation (Figure 2.7D). This result indicates that post-hypoxia potentiation is mediated 
through A2AR activation, which has been shown to induce PKA activation, which in turn 
phosphorylates GluA1 causing increased GluA1 surface expression (Dias et al., 2012), which 
is consistent with experiments above (Figure 2.5, 2.6).  
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Figure 2.7. A2AR inhibition abolished Adenosine-induced post-hypoxia potentiation 
(APHP) in CA1 hippocampal slices following 20min hypoxia and normoxic reperfusion. 
(A) Representative fEPSP at experimental time points of the final 10 traces (5min) prior to 
the end of a treatment period (20min baseline, 20min hypoxia, 45min normoxic reperfusion). 
fEPSP traces in column 1 (far left) show representative fEPSP traces for the final 5min of the 
baseline recording period. Column 2 (second from the left) shows traces at the end of 
hypoxia treatment, and column 3 (third from the left) shows traces at the end of the 45min 
normoxic reperfusion period. Finally, column 4 (titled 1+2+3, right side) shows an overlay of 
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each of the 3 traces for each treatment group. Scale bars are 0.25mV in the Y-axis and 10ms 
in the X-axis. (B) fEPSP time-course plot of the average normalized fEPSP slopes for each 
drug incubation. (C) Summary bar graph showing the average of the final 10 sweeps of each 
treatment group at the end of the 20min hypoxia period. During hypoxia in the presence of 
SCH442416 with various protein phosphatase inhibitors, there is no significant difference 
between any of the treatment groups, indicating that A2ARs do not affect hypoxia-induced 
synaptic depression. (D) Summary bar graph of fEPSPs after 45min normoxic washout. In 
normoxic reperfusion, the addition of SCH442416 (5nM) to hippocampal slices abolished 
post-hypoxia potentiation. (E) Bar graph showing the comparison between the difference of 
normalized fEPSP slope without (from Figure 2.4) vs. with SCH442416 in the final 5min of 
the hypoxia treatment. Results show that there were no significant differences between the 
values with or without SCH442415 treatment. (F) Bar graph showing a similar comparison as 
in E, except calculated using values taken at the end of the normoxic washout period. 
SCH442415 reduced fEPSP values the most in control (DMSO) slices, whereas FK506-
treated slices showed significantly less of a difference with or without SCH442416 treatment. 
N = 7-9 separate experiments for each treatment. Values are shown as mean ± SEM. 
Significance values: * = p<0.05, ** = p<0.01, *** = p<0.005. Data was acquired with the 
assistance of Dr. Zhi Ming: Dr. Ming performed fEPSP recordings, and experimental design, 
collection of preliminary data, and data analysis were performed by myself.  
 
2.4.8 Protein phosphatase inhibitor pre-incubation reduced neuronal death in pyramidal 
CA3-CA1, with significant neuronal protection in CA1 of hippocampal slices after 20min 
hypoxic insult.  
To test the neuroprotective potential of these protein phosphatase inhibitor drugs used in 
these experiments, propidium iodide (PI) fluorescent staining was used, which selectively 
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stains dead cells with disrupted plasma membranes (Pugliese et al., 2009). The PP2B 
inhibitor FK506 has been shown to be neuroprotective in various in vitro and in vivo 
preparations (Sharkey and Butcher, 1994; Butcher et al., 1997; Bochelen et al., 1999; Uchino 
et al., 2002), and due to similar effects of PP1 and PP2A inhibitors found in the above 
figures, we hypothesized that these treatments would show neuroprotection in hippocampal 
slices subjected to a prolonged 20min hypoxic insult.   
Hippocampal slices were pre-incubated in the protein phosphatase inhibitors okadaic acid 
(3nM), fostriecin (20nM), tautomycetin (20nM), and FK506 (50nM) for 1h followed by a 
20min hypoxic insult. It is important to note that okadaic acid has been shown to cause 
neuronal death alone (Nuydens et al., 1998), so a lower concentration (3nM compared to 
20nM) of okadaic acid was used in this experiment to reduce the chance of inducing okadaic 
acid-induced neuronal death. Following a 3h incubation and PI staining in the final hour of 
incubation, slices were fixed in paraformaldehyde and imaged using a Zeiss LSM700 laser 
scanning confocal microscope. Resultant images show that hypoxia control (DMSO) caused 
significant neuronal death in CA1 compared to time control slices (Figure 2.8A,G). All four 
protein phosphatase inhibitor treatments significantly reduced neuronal death after hypoxia, 
with neurodegeneration seen in fostriecin and FK506-treated slices were significantly less 
than DMSO (Figure 2.8D,E). These results indicate that protein phosphatase inhibitors afford 
neuroprotection to hippocampal slices subjected to a prolonged hypoxic insult.  
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Figure 2.8 Protein phosphatase inhibitor treatment reduced neurodegeneration in 
hippocampal slices following 20min hypoxia. Propidium iodide-labeled hippocampal slice 
montages show representative slices for each treatment group (A-F). (A) Control  (DMSO) 
hypoxia slices showed high levels of neuronal death in the dentate gyrus and CA3-CA1 (left 
panel). The right panel shows two representative combined Z-stack images of CA1 showing 
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significant neuronal death. (B) Slices treated with the PP1 inhibitor tautomycetin (20nM) 
showed reduced neuronal death in all hippocampal regions (left panel) and Z-stack images of 
CA1 (right two panels) show reduced neuronal death. (C) Representative slice treated with 
Okadaic Acid (3nM) showing both the whole hippocampus (left) and two Z-stack images 
(right) (D) Representative images of whole hippocampal slices (left) treated with FK506 
(50nM) prior to hypoxia, with two Z-stack images (right) on CA1.  (E) Representative 
images of fostriecin-treated hippocampal slice (20nM), panels same as above. (F) 
Representative time control slice images showing the least neurodegeneration. (G) Summary 
bar graph showing mean densitometry values normalized to the time control values (100%). 
Representative Z-stack images are shown as a maximum intensity image of 20µm inside 
400µm thich hippocampal slices. n = 4 independent experiments, using 5 rats per 
experiment.. Values are shown as mean ± SEM. Significance values: * = p<0.05, *** = 
p<0.005. 
 
2.5 Discussion 
In this study, we investigated the role of protein phosphatases 1, 2A and 2B in adenosine-
mediated synaptic depression in hypoxia/reperfusion injury in rat hippocampal slices, and 
their role in regulating AMPA receptor surface expression. We show that these three protein 
phosphatases mediate A1R-induced GluA1 endocytosis by reducing the phosphorylation of 
Ser831 and Ser845 GluA1 C-terminal residues. PP1, PP2A and PP2B inhibition reduced 
CPA-induced GluA1 internalization, but only PP2A inhibition prevented CPA-induced 
GluA2 endocytosis. Accordingly, the levels of GluA1 pSer831 and pSer845 were reduced by 
CPA, and this reduction in pSer831 and pSer845 was prevented by treatment of hippocampal 
slices with PP1, PP2A and PP2B inhibitors. Along with reducing AMPAR surface 
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expression, prolonged A1R activation induced APSD (Chen et al., 2014), which was reduced 
by pre-treating hippocampal slices in PP1, PP2A or PP2B inhibitors.  
After a 20min hypoxic insult, both control and protein phosphatase inhibitor-treated 
hippocampal slices showed fEPSP recovery in normoxic reperfusion above baseline, which 
we have termed adenosine-induced post-hypoxic potentiation (APHP) (Figure 2.4). 
Treatment with SCH442415 (5nM), an A2AR antagonist, prevented APHP (Figure 2.7), 
indicating that A2AR activation following oxygen reperfusion after hypoxia mediates APHP, 
potentially enhanced by A1R desensitization after hypoxia (Chen et al., 2014). Based on 
these data we sugest that hypoxia-induced A1R activation influences A2AR activity in 
reperfusion. 
Slices subjected to 20min hypoxia followed by 45min normoxic reperfusion/washout 
showed increased surface GluA1, but not GluA2, levels during reperfusion-induced APHP, 
which was prevented by pre-treatment with SCH442416 (Figure 2.5). Increased GluA1 
surface expression after washout was accompanied by increased pSer831 and pSer845 levels, 
which was also prevented with SCH442416 treatent (Figure 2.6). Finally we found that, 
protein phosphatase inhibitor treatments prior to a 20min hypoxic insult were shown to be 
neuroprotective in hippocampal slices. Our study reports a novel mechanism mediating a 
functional interaction between A1Rs and GluA1, where protein phosphatases induced GluA1 
endocytosis following A1R activation.  
PP1, PP2A and PP2B have been shown to contribute to the modulation of excitatory 
neurotransmission and learning and memory processes throughout the brain through a 
multitude of intracellular mechanisms (Mulkey et al., 1993; Lin et al., 2000; Belmeguenai 
and Hansel, 2005). For example, PP1 activity has been shown to mediate the induction of 
LTP and LTD (Allen et al., 2000; Li and Pan, 2013), and has been shown to directly regulate 
AMPA receptors in the brain (Yan et al., 1999). In addition to previously described A1R-
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induced increase in active PP2A in the postsynaptic density (Brust et al., 2006), PP2A has 
also been shown to mediate multiple functions in the brain which also includes direct 
modulation of AMPARs (Launey et al., 2004). It has also been shown that the levels of the 
regulatory B subunit of PP2A is decreased after focal ischemia, which indicates increased 
PP2A activity (Koh, 2011). Finally, PP2B, a Ca2+-dependent protein phosphatase, has been 
implicated in the induction of neurotoxicity in ischemia (Ankarcrona et al., 1996; Asai et al., 
1999), whereas inhibition of PP2B with FK506 is an effective neuroprotectve treatment 
FK506(Sharkey and Butcher, 1994; Butcher et al., 1997; Bochelen et al., 1999; Uchino et al., 
2002). In this study, we add to the wide list of functions performed by these three ubiquitous 
protein phosphatases.  
We recently showed that p38 MAPK and JNK mediate A1R-induced GluA2 endocytosis, 
with a smaller effect on GluA1 endocytosis, and PP2A is involved in both GluA1 and GluA2 
endocytosis (Chen et al., 2014). The results of this chapter show a novel mechanism by 
which adenosine modulates synaptic activity in the hippocampus in hypoxic injury through 
the activation of PP1, PP2A and PP2B, which induce GluA1 internalization through 
reduction in the phosphorylation of Ser831 and Ser845. Previous reports have described the 
involvement of these three protein phosphatases in various ischemia-induced cellular 
mechanisms in the brain (Rundén et al., 1998; Cid et al., 2007). For example, PP1, PP2A, and 
PP2B were shown to play a role in estrogen-mediated neuroprotection in ischemia, where 
inhibition of these protein phosphatases reduced estrogen-mediated neuroprotection after 
transiet middle cerebral artery occlusion (tMCAO) in vivo stroke model, supporting a 
neurodegenerative effect of protein phosphatase 1, 2A and 2B inhibition (Walsh et al., 1997). 
In contrast, our results indicate a neuroprotective action of okadaic acid, fostriecin, 
tautomycetin and FK506, which supports a neurprotective effect of the inhibition of PP1, 
PP2A and PP2B (Figure 2.8). Although these results appear to contradict, it is important to 
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consider that these three protein phosphatases are ubiquitous and have a wide range of 
substrates and activators, and these two studies used two different models, one being in vivo 
and this study being in vitro.  
It has been recently shown that a 10min oxygen-glucose deprivation (OGD) insult to 
hippocampal slices induced a reduction in excitatory postsynaptic currents (EPSCs) followed 
by increased recovery above baseline levels, which has been termed ischemia-induced long-
term potentiation (i-LTP) (Dias et al., 2013). The use of 20min hypoxia in the current study 
mimicked the effect seen by Dias et al. (2013), showing significant synaptic depression in 
hypoxia followed by fEPSP potentiation during normoxic reperfusion. Both i-LTP and APHP 
involve A2AR activation and increased CP-AMPAR activity, and potentiation can be 
reduced by either A2AR inhibition or CP-AMPAR inhibition (Dias et al., 2013). These data 
indicate that GluA1-containing AMPARs and A2ARs are key mediators of reperfusion injury 
to neurons by inducing increased Ca2+ permeability, thus increasing the chance of 
excitotoxicity. GluA1 and GluA2 are the most abundantly expressed AMPAR subunits in the 
brain and the presence or absence of GluA2 in a functional tetramer receptor confer Ca2+-
permeability to the receptor (Rogers et al., 1991). Increase CP-AMPAR surface expression is 
a known mechanism for the induction of LTP (Szabo et al., 2012), which shows similarities 
to i-LTP, except that CP-AMPAR expression is transient in LTP, whereas it is more 
prolonged in i-LTP (Szabo et al., 2012), which may explain why CP-AMPAR expression is 
not neurotoxic in LTP induction.  
Finally, propidium iodide was used to label hippocampal slices for neurodegeneration, and 
protein phosphatase 1, 2A and 2B inhibitor drug pre-treatments reduced the amount of 
neurodegeneration caused by a 20min hypoxic insult. By inhibiting PP1, PP2A, or PP2B, 
A1R-mediated AMPAR internalization is reduced (Esteban et al., 2003; Lu and Roche, 
2012), which would contribute to increased neuronal excitability in hypoxia. In particular, 
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since p38 MAPK and JNK also mediate A1R-induced GluA2 internalization (Chen et al., 
2014), there may be increased GluA1-containing AMPAR surface expression with reduced 
GluA2-containing AMPAR surface expression. Increased GluA1 surface expression through 
reduced internalization and increased pSer831 and pSer845 has been shown to increase 
neuronal excitation and increase Ca2+ permeability (Liu and Zukin, 2007). Additionally, 
increased GluA2 internalization has been shown to induce pro-apoptotic intracellular signals 
(Gorter et al., 1997) Interestingly, fEPSP experiments show that protein phosphatase 
inhibition did not prevent APHP following 20min hypoxia, except in the case of FK506 
(Figure 2.7). This is important because APHP may be associated with excitotoxicity (Dias et 
al., 2012). To elucidate the mechanism of protein phosphatase inhibitor-induced 
neuroprotection while not preventing APHP in normoxic washout, further research is 
required to test the involvement of other receptors (eg. NMDARs) and intracellular kinases or 
phosphatases in these effects.   
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Chapter 3: Regulation of extracellular adenosine levels by 
the interaction of adenosine A1 receptors, casein kinase 2, 
and equilibrative nucleoside transporters in hypoxia and 
focal cortical ischemia in rat hippocampal slices 
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3.1 Summary 
Dynamic regulation of the levels of extracellular adenosine occurs in both physiologically- 
and pathophysiologically-induced cellular reactions to various normal and noxious stimuli in 
the hippocampus. In hypoxia or ischemia, adenosine levels rapidly increase up to 100 times 
above normal levels, and mediate rapid synaptic depression through activation of high-
affinity adenosine A1 receptors (A1Rs), which are responsible for synaptic depression. 
Additionally, equilibrative nucleoside transporters (ENTs), which are abundantly expressed 
in the hippocampus, allow passive transport of adenosine across cell plasma membranes. Due 
to the passive transport of ENT channels, a major mechanism of the regulation of adenosine 
transport through ENTs is by the modulation of ENT surface expression. In this chapter, 
casein kinase 2 (CK2) will be investigated as a potential modulator of adenosine-induced 
neuronal responses. CK2, a ubiquitous serine/threonine kinase, has been implicated in a wide 
array of intracellular signaling activity in the hippocampus. The ENT1 channel subtype 
contains intracellular amino acid consensus sequences that are targeted by CK2, indicating 
that CK2 may play a role in ENT1 regulation. Paired pulse fEPSP experiments in CA1 of rat 
hippocampal slices were performed to assess the effect of CK2 and ENT inhibitors on 
adenosine tone. Results indicate that there was increased adenosine A1R activation following 
CK2 or ENT inhibitor treatments. Additionally, fEPSPs with a 20min hypoxic insult were 
performed to assess the effect of CK2 and ENT inhibitors on the electrophysiological 
response to hypoxia. Inhibition of CK2 or ENT1 and ENT2 induced increased extracellular 
adenosine tone, and also reduced hypoxia-induced synaptic depression and prevented 
adenosine-induced post-hypoxia potentiation (APHP). Additionally, CK2 inhibitor treatment 
was shown to be neuroprotective after a 20min hypoxic insult. These results indicate that 
CK2 regulates ENT1 following its activation  by A1Rs. Finally, this chapter examines the 
paired-pulse ratio before and after A1R inhibition in hippocampal slices taken from rats 48 
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hours after pial vessel disruption (PVD) small vessel cortical stroke surgery. PVD animals 
showed significantly different effects after A1R inhibition, suggesting that PVD induced 
changes in adenosine signaling in the hippocampus.. These data illustrate the importance of 
the regulation of extracellular adenosine, and suggest CK2 as a potential therapeutic target 
for future studies.   
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3.2 Introduction 
Equilibrative nucleoside transporters (ENTs) are a major mediator of the movement of 
adenosine and other nucleosides such as guanosine across cell membranes, and they are 
dynamically regulated (Anderson et al., 1999; Baldwin et al., 2004). In hypoxia and cerebral 
ischemia, extracellular adenosine increases appreciably (Dale et al., 2000), with two potential 
sources being adenosine extruded from ischemic cells and from extracellular adenosine 
metabolism by ectonucleotidases (Latini et al., 1996b). It has been shown that the high-
affinity adenosine A1 receptor (A1R) is highly activated in the hippocampus following 
increased extracellular adenosine concentrations (Andersen et al., 1999; Huang et al., 1999).  
Adenosine is a ubiquitous nucleoside that can be transported across plasma membranes by 
two classes of nucleoside transporters: concentrative nucleoside transporter (CNT) pumps, 
and equilibrative nucleoside transporter (ENT) channels (Nagy et al., 1990; Dunwiddie and 
Masino, 2001). Additionally, casein kinase 2 (CK2) has been shown to play a role in subtype-
specific modulation of ENT action, suggesting it as a regulatory second messenger for ENTs 
(Stolk et al., 2005). CK2 is an endogenous serine/threonine kinase that preferentially targets 
specific consensus sequences, one of which is present on the intracellular portion of ENT1 
(Bone et al., 2007). Additionally, CK2 has been shown to preferentially phosphorylate ENT1 
in neurons (Stolk et al., 2005), and CK2 has high basal levels of activity, but its activity can 
be modulated (Litchfield, 2003; Ye et al., 2011).  
Studies in Chapter 2 showed that a 20min hypoxic insult followed by normoxic 
reperfusion induced adenosine-induced post-hypoxia potentiation (APHP), which is similar 
to ischemia-induced LTP (i-LTP) found using OGD studies on hippocampal slices. After 
reperfusion, APHP was prevented by adenosine A2AR inhibitor treatment, indicating that 
APHP is induced by increased A2AR activity following reperfusion. Adenosine A1R 
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signaling has been shown to increase during hypoxia, which mediates A1R-mediated 
synaptic depression (Van Wylen et al., 1986; Coelho et al., 2006; Chen et al., 2014). 
In this study, we tested the hypothesis that CK2 regulates the activity of ENTs, which 
modulate extracellular adenosine tone in the brain. Hippocampal slices were incubated in 
ENT or CK2 inhibitor drug treatments followed by fEPSP experiments using a selective A1R 
antagonist (DPCPX), which reveals increased adenosine tone in hippocampal slices treated 
with ENT and CK2 inhibitors compared to control. Slices with the same treatments were then 
subjected to a 20min hypoxic insult and a 45min normoxic washout. After 20min hypoxia, 
hippocampal slices labeled for neurodegeneration with propidium iodide showed 
neuroprotection with the use of CK2 inhibitor treatments. Additionally, 2 days following 
PVD surgery, hippocampal slices in PVD rats showed altered adenosine-mediated signaling 
in CA1, indicating that a small cortical lesion may modulate functioning throughout the 
brain.  
 
3.3 Methods 
3.3.1 Hippocampal slice preparation 
Sprague-Dawley rats at postnatal day 18-30 (pn18-30) (Charles River, Canada) were 
anaesthetized with halothane and decapitated according to protocols approved by the 
University Committee of Animal Care and Supply (UCACS) at the University of 
Saskatchewan. Brains were quickly extracted and placed in ice-cold oxygenated dissection 
medium containing the following (in mM): NaCl, 25 NaHCO3, 25 glucose, 75 sucrose, 2.5 
KCl, 1.25 NaH2PO4, 7.0 MgCl2, and 0.5 CaCl2. Hippocampal slices (400µm thick) were cut 
using a vibrating tissue slicer (Leica VT1200S, Germany) and maintained for 1h at room 
temperature in artificial cerebro-spinal fluid (aCSF) containing the following (in mM): 126 
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NaCl, 2.5 KCl, 2.0 MgCl2, 1.25 NaH2PO4, 26 NaHCO3, 10 glucose, 2.0 CaCl2, and aerated 
with 95% O2/5% CO2.  
3.3.2 Drug Treatments 
Following the 1h equilibration period, hippocampal slices were then treated with one of 
the following: dimethylsulfoxide (DMSO, vehicle control), dipyridamole (DPY) an ENT1/2 
inhibitor (10µM), S-(4-Nitrobenzyl)-6-thioinosine (NBTI), an ENT 1 inhibitor (100nM), or 
dichlororibofuranosylbenzimidazole (DRB), a CK2 inhibitor (100µM) for 1h. During the 
experiment, 8-cyclopentyl-1,3-dipropylxanthine (DPCPX, 100nM, A1R antagonist) and 
SCH442416 (SCH, 5nM, A2AR antagonist) were used as well. All chemicals were obtained 
from Sigma-Aldrich and diluted as stock solutions in DMSO before being added to aCSF. 
The final concentration of DMSO was <0.1% in all solutions. 
3.3.3 Pial vessel disruption as a model of small-vessel stroke 
Disruption of class II size vessels on the surface of the cortex (pia), known as pial vessel 
disruption (PVD), induces a small cortical lesion that forms a lacuna-like fluid-filled cyst in 
the area of the lesion within three weeks of PVD surgery (Wang and Walz, 2003; Wang et 
al., 2004; Cayabyab et al., 2013; Chen et al., 2014). Importantly, this lesion is confined to the 
cortex, and thus the lesion does not extend into the underlying corpus callosum (Wang and 
Walz, 2003). Surgeries were performed as described previously (Hua and Walz, 2006). In 
short, PVD surgery induced an approximately 1mm3 permanent (ie. Non-reperfusion) lesion 
in the cortex. Rats weighing approximately 250g were anaesthetized with 2% isofluorane and 
buprenorphine was given for analgesic effects. Anaesthetized rats received a 5mm-diameter 
craniotomy on the right, rostral side of the bregma adjacent to the coronal sagittal structures. 
The dura was then opened, and ClassII pial vessels were disrupted using small forceps. The 
removed piece of skull was then replaced and the wound was closed with a suture clip. Rats 
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were then given 48h recovery time and were then sacrificed, and hippocampal slices were 
taken as described above.  
3.3.4 Electrophysiology 
Following the 1h drug incubation, hippocampal slices were placed in a recording chamber 
and perfused with aerated aCSF at a rate of 3ml/min. Perfused aCSF contained the same 
concentration of drug treatment as was used in the pre-incubation treatments. Field excitatory 
postsynaptic potentials (fEPSPs) were evoked by a tungsten bipolar stimulating electrode, 
which was placed in CA1 along the Schaffer collateral pathway. fEPSP response was 
recorded by a glass microelectrode placed in the CA1 stratum radiatum. fEPSP signals were 
recorded using a Digidata 1440A digitizer (Axon Instruments, Foster City, CA) and saved 
using Clampex 9.0 (Axon Instruments). fEPSPs were evoked at 30s intervals using a paired 
pulse stimulation protocol or a single pulse protocol.  
Each experiment recorded a stable baseline as in Chapter 2 prior to experimental 
treatments. A paired-pulse experiment was used to assess adenosine tone and 
neurotransmitter release with pre-treatment in CK2 and ENT inhibitors. Two pulses 50ms 
apart were evoked every 30s through the course of the experiment. Following a 20min 
baseline recording, 100nM DPCPX, a selective A1R antagonist, was perfused in solution for 
30min in the presence of the inhibitors listed above. The paired-pulse ratio (PPR) was 
assessed by finding the ratio of the slope of the second pulse (P2) to the slope of the first 
pulse (P1) from each measurement. In a subsequent experiment, following a 20min baseline 
recording, slices were subjected to a 20min hypoxic insult followed by a 45min normoxic 
washout period. Hypoxia was achieved by bubbling aCSF with 95%N2/5%CO2 for a 
minimum of 20min prior to the experiment starting, and continually through the experiment 
to deplete oxygen in solution. The gas was balanced with 5% CO2 to keep pH within a 
physiological range. 
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3.3.5 Propidium Iodide Staining  
The methods used to stain hippocampal slices with propidium iodide (PI) were adapted 
from Pugliese et al. (2009). Following equilibration of hippocampal slices for 1h after slicing, 
the following drug treatments were added: the CK2 inhibitors DMAT and TBB, and the CK2 
activator Spermine. Slices that were treated with spermine were also treated with D-APV to 
prevent aberrant NMDAR activation due to spermine for 1h. Hippocamap slices were then 
subjected to a 20min hypoxic insult by replacing oxygenated aCSF with hypoxic aCSF that 
was bubbled with 95%N2/5%CO2 prior to, and continuously throughout the hypoxic insult. 
After 20min hypoxia, aCSF was replaced with normoxic aCSF and the slices were incubated 
at room temperature for 3h. During the final 1h incubation period, 5µg/ml propidium iodide 
(Sigma) was added to the aCSF. Following the incubation period, slices were rinsed 
thoroughly in aCSF and then fixed in 4% paraformaldehyde at 4°C overnight. The following 
day, slices were washed 3 x 15min in 1X PBS and then mounted on glass microscope slides 
(VWR) and sealed using Prolong Gold Antifade Reagent (Invitrogen). After the addition of 
PI, all subsequent procedures were done in the dark to prevent photobleaching.  
Hippocampal slices were imaged using a Zeiss LSM700 laser scanning confocal 
microscope (Carl Zeiss, Germany) using green light (543nm) to induce PI fluorescence. The 
whole hippocampus was imaged in pieces using a 10x objective lens, and images of CA1 
pyramidal neurons were obtained using the Zeiss Plan-Apochromat 63x/1.6 oil objective lens 
(Carl Zeiss). CA1 images were acquired as Z-stack images of 200µm depth into the 
hippocampal slice to the outer top of the slice, with each Z-stack image taken at 2µm (total 
100µm). Two Z-stack images were taken along CA1 for each slice.  
Data was collected using Zeiss Zen 2009 v. 5.5 software (Carl Zeiss) and was analyzed 
using ImageJ (NIH, public domain). Z-stack images closest to the outer top and bottom of the 
hippocampal slices were not analyzed, as the neuronal damage in those areas was enhanced 
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by the slicing procedure. The inner-most 20µm segments (~100µm down) were combined as 
maximum intensity projections and intensities were compared between treatment groups. 
Densitometry analysis was performed on CA1 Z-stack maximum intensity projection images, 
and densitometry values were normalized to time control slices that were treated along with 
each experiment. Data was graphed as a percentage of the time control value and analyzed 
for significance against this control value (100%). Full hippocampal images were assembled 
as montages of the entire hippocampal slice using Adobe Photoshop CS6 (Adobe Systems, 
Mountain View, CA).  
 
3.4 Results 
3.4.1 CK2 and ENT inhibition increased adenosine tone in CA1 of rat hippocampal slices 
To assess the functional effect of ENT and CK2 inhibition on adenosine tone and the 
probability of neurotransmitter release, we performed paired-pulse fEPSP recordings in CA1 
of rat hippocampal slices that were pre-incubated in NBTI (100µM), DRB (100µM), or DPY 
(10µM) followed by inhibition of A1Rs using the selective antagonist DPCPX (100nM). We 
hypothesized that inhibition of CK2 and ENT1/ENT2 would inhibit adenosine transport and 
thus increase extracellular adenosine tone. Blockade of A1Rs was therefore hypothesized to 
increase synaptic transmission in hippocampal slices pre-treated in CK2 and ENT inhibitors. 
As shown in Figure 3.1, during perfusion of DPCPX, fEPSPs were significantly increased 
with both ENT and CK2 inhibitor treatments compared to control (DMSO). Blockade of 
A1Rs removes A1R-mediated synaptic depression both presynaptically and postsynaptically. 
Results indicated an increase in both adenosine concentration and A1R activation. The 
paired-pulse ratio (PPR) decreases significantly more than control with NBTI, DPY, and 
DRB incubated hippocampal slices (Figure 3.1C), indicating paired-pulse depression (PPD), 
or an increase in the probability of neurotransmitter release, when treated with 30min 
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DPCPX. These results indicate that both CK2 and ENT inhibition increases adenosine tone 
and that both proteins are involved in the regulation of basal adenosine tone in the 
hippocampus.  
 
Figure 3.1. CK2 and ENT inhibition increased adenosine tone in hippocampal slices. 
Paired-pulse fEPSP recordings in CA1 of rat hippocampal slices pre-treated with CK2 
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inhibitor (DRB, 100µM), ENT1 inhibitor (NBTI, 100nM), or ENT1/ENT2 inhibitor (DPY, 
10µM) and perfused with DPCPX (100nM) for 30min. (A) Representative fEPSP traces for 
treatment groups DMSO (control), NBTI, and DRB. 1 (Left): Average paired-pulse traces as 
an average of the final 10 sweeps during baseline recording. 2 (Middle): Average paired-
pulse traces of the final 10 sweeps of 30min DPCPX treatment. 1+2 (Right): Overlay of 
baseline and DPCPX treatments together. Scale bars represent 0.25mV, 10ms. (B) Left. Time 
course plot of fEPSP slope (10min baseline, 30min DPCPX treatment) normalized to the final 
10 sweeps of baseline recording (100%). After 30min DPCPX, fEPSPs were significantly 
potentiated between 300-500% of baseline with CK2 and ENT inhibitor pre-treatment and no 
significant change in DMSO. Right. Summary bar chart shows CK2 and ENT inhibitors 
significantly increased fEPSP slope after 30min DPCPX treatment. (C) Left. Time course plot 
of paired-pulse ratio (PPR) over course of the experiment. During baseline (1) PPR was 
approximately 1 (100%) for each treatment group. After 30min DPCPX treatment (2) PPR 
was significantly reduced (paired-pulse depression, PPD) in CK2/ENT inhibitor pre-treated 
groups. Right. Summary bar chart showing that CK2 and ENT inhibitor pre-treatment 
significantly reduced PPR after 30min DPCPX treatment, indicating PPD. Average values are 
mean±SEM, n=3-6 independent experiments, each from different rats, * P<0.05, ** P<0.01 
and *** P<0.001.. 
 
3.4.2 ENT1/2 inhibition reduced hypoxia-induced synaptic depression in hypoxia and 
ENT1/2 and CK2 inhibition reduced post-hypoxic potentiation in CA1 of rat hippocampal 
slices 
To examine the functional effects of enhanced reduction of surface expression of ENTs 
and A1Rs with 20min hypoxia in the presence of ENT and CK2 inhibitors found within this 
lab, we performed fEPSP recordings on hippocampal slices pre-treated in NBTI, DRB, or 
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DPY with a 20min hypoxic insult followed by a 45min normoxic washout period. Figure 3.2 
shows that both treatment with DPY, an ENT1 and ENT2 inhibitor, and DRB, a CK2 
inhibitor, significantly reduced hypoxia-induced synaptic depression compared to control 
(DMSO) and NBTI (ENT1 inhibitor) treatments. NBTI did not significantly affect hypoxia 
induced synaptic depression.  
During normoxic washout (Figure 3.2B,C), control CA1 fEPSPs rapidly recovered to 
baseline and continued to increase and become potentiated significantly above baseline 
levels. This post-hypoxic potentiation was reduced significantly with DPY, DRB, and NBTI 
treatment. This suggests that ENT1/ENT2 and CK2 activity during hypoxia reperfusion is 
involved in potentiation of neurotransmission in the hippocampus. These results indicate a 
correlation between decreased A1R and ENT surface expression with CK2 and ENT 
inhibition and reduced hypoxia-induced synaptic depression. 
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Figure 3.2. CK2 and ENT1/ENT2 inhibitors reduced hypoxia-induced synaptic 
depression and CK2 and ENT inhibitors decreased potentiation during normoxic 
reperfusion. (A) Representative fEPSP traces for each treatment group: DMSO (control), 
NBTI (ENT1 inhibitor, 100nM), DPY (ENT1/ENT2 inhibitor, 10µM), DRB (CK2 inhibitor, 
100µM), and SCH (A2AR inhibitor, 5nM). 1. Baseline fEPSP traces. 2. fEPSP traces with 
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20min hypoxia treatment. 3. fEPSP traces after 45min normoxic washout. 1+2+3. Overlay of 
representative traces for each treatment group shown to the left. Scale bars represent 0.25mV, 
10ms. (B) Time course plot showing average data for each treatment group throughout the 
course of the experiment. 1. Final 10min of baseline recording. 2. Hypoxia treatment period 
(20min). 3. Normoxic washout period. During hypoxia, both DPY and DRB significantly 
reduced hypoxia-induced synaptic depression compared to control (DMSO) and NBTI. 
During normoxic washout, inhibitor treatments (NBTI, DPY, DRB) reduced post-hypoxic 
potentiation seen in control. (C) Summary bar charts showing the mean of the final 10 traces 
from 20min hypoxia (left), and 45min normoxic washout (right) normalized as a percentage 
of baseline levels (100%). In hypoxia, DRB and DPY both significantly reduced the amount 
of synaptic depression compared to both DMSO and NBTI. In washout, NBTI, DRB, SCH, 
and DPY significantly reduced potentiation seen in control. Average values are mean±SEM, 
n=6-12 independent experiments from different rats, * P<0.05, ** P<0.01 and *** P<0.001. 
 
3.4.3 CK2 inhibition provided neuroprotection to hippocampal slices after 20min hypoxia.  
The role of CK2 as a potential neuroprotective protein has been explored (Kim et al., 
2009), but the direct effect of CK2 inhibition or activation in neuroprotection or 
neurodegeneration in hypoxia or ischemia have not been well established. To test the effect 
of CK2 in hypoxia-induced neurodegeneration, hippocampal slices were pre-treated with 
DMAT or TBB, which are both CK2 inhibitors, or with Spermine, which is a CK2 activator, 
or, due to the ability for spermine to also activate NMDA receptors by direct interaction, we 
also treated slices with Spermine + D-APV, an NMDAR inhibitor. Following a 20min 
hypoxic insult, slices were reintroduced to normoxic conditions and incubated for 3h prior to 
fixation. In the final hour of incubation, propidium iodide (PI) was added to label dead cells 
for neurodegeneration. Figure 3.3 shows that hypoxia alone induced significant 
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neurodegeneration (Figure 3.3B), whereas slices treated with DMAT and TBB showed 
significantly less neurodegeneration than hypoxia alone (Figure 3.3C-E) Time control slices 
showed significantly less neurodegeneration than hypoxia control (DMSO), and densitometry 
analysis was performed with densitometry values normalized to time control (100%). DMAT 
and TBB treatment prior to hypoxia were shown to be neuroprotective, while spermine did 
not prevent hypoxia-induced neurodegeneration. Spermine with the NMDAR inhibitor D-
APV was also neuroprotective, indicating that CK2 activation may contribute to 
neurodegeneration through increasing NMDAR activity. These data suggest that inhibition of 
CK2 activity, or reduced CK2 activation, affords neuroprotection to hippocampal neurons.  
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Figure 3.3. CK2 inhibitor treatment reduced neurodegeneration caused by a 20min 
hypoxic insult in hippocampal slices. (A) Representative propidium iodide staining images 
of time control hippocampal slices, which were not subjected to any drug treatments or 
hypoxic conditions. There is very little neurodegeneration seen in these slices, and all treated 
slices were normalized to the time control values (100%). (B) Slices treated with DMSO with 
hypoxia showed significant neurodegeneration approximately 450% of time control values. 
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(C) Slices treated with DMAT showed significantly less neurodegeneration compared to 
DMSO. (D) Representative slice treated with the CK2 inhibitor TBB. (E) Representative 
hippocampal images showing increased neurodegeneration in slices treated with spermine 
alone. (F)Representative slice showing treatment with spermine and D-APV. (G) Summary 
bar graph showing values of average intensity normalized to time control values (100%). 
Average values are shown as mean ± SEM with arbitrary units, n=4 independent 
experiments, 5 rats per experiment. Significance values * P<0.05 and *** P<0.001. 
 
3.4.4 Focal cortical ischemia in an in vivo PVD small-vessel stroke model contributes to 
tonic synaptic depression by increasing adenosine tone in the hippocampus. 
Many focal cerebral ischemia models involve occlusion of large cerebral blood vessels 
such as the middle cerebral artery, which results in damage to the striatum and cortex to 
varying degrees depending on the duration of vessel occlusion (Traystman, 2003). During 
hypoxia, transient global ischemia or focal cerebral ischemia, it is well accepted that there is 
an increase in the extracellular levels of adenosine. Brain damage in global and focal 
ischemia models occurs within selectively vulnerable areas such as the hippocampal CA1 
region, neocortex, and striatum. Global ischemia has been shown to selectively reduce the 
expression of GluA2-containing AMPARs in the CA1 region in rats (Sommer and Kiessling, 
2002). In this study, we have used a modified pial vessel disruption (PVD) protocol, which 
mimics mild, small-vessel strokes. This involves permanent disruption of class II size pial 
vessels, and has been shown to produce a consistent cone-shaped cortical lesion damage that 
does not extend to the corpus callosum (Wang and Walz, 2003; Hua and Walz, 2006).  
In this study, we hypothesized that adenosine surges in the brain will be sufficiently 
prolonged to induce increased adenosine tone in the hippocampus 48h post-PVD surgery.   
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Since it is widely accepted that adenosine is tonically elevated during cerebral ischemia 
(Dale et al., 2000), we tested the hypothesis that adenosine surges in the brain after 
permanent focal disruption of small cortical pial vessels may be sufficient to affect vulnerable 
brain regions, such as the hippocampus, and influence the induction of synaptic depression. 
Therefore, we evaluated the effects of PVD vs. sham surgeries on synaptic transmission two 
days post surgeries. The fEPSP recordings from hippocampal slices were obtained from the 
ipsilateral side of PVD surgery lesion or sham surgery. Consistent with a downregulation of 
A1Rs after PVD, we observed less synaptic potentiation and paired-pulse depression when 
the A1R antagonist DPCPX was applied to the PVD slices compared to sham brains (Figure 
3.3A-B).  
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Figure 3.4. PVD model of focal cortical cerebral ischemia leads to increased synaptic 
depression in hippocampus. (A) Hippocampal slices from sham-operated or PVD-lesioned 
brains were exposed to 500nM DPCPX for 30min to assess the level of synaptic depression 
(reflecting adenosine tone). DPCPX induced greater synaptic transmission in sham vs. PVD 
hippocampal slices. (B) Responses to paired pulses (50ms apart) revealed greater paired-pulse 
depression in sham vs. PVD hippocampal slices. Values in A-B are means±SEM from 4 
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independent experiments (4 animals each), with *P<0.05 and **P<0.01 unpaired Student’s t-
test. Calibration: 0.5mV, 5ms in A, and 10ms in B. The numbers “1” and “2” associated with 
figure traces and time course charts correspond to fEPSPs at baseline and fEPSP in DPCPX, 
respectively.  
 
3.5 Discussion  
This chapter focused on investigating a functional ENT/CK2 interaction, potential 
neuroprotection through CK2 inhibition, and alterations in adenosine tone 48h following 
PVD surgery. Both ENT1 and ENT2 are expressed ubiquitously in mammalian cells, and are 
distributed throughout the central nervous system, including the hippocampus (Jennings, 
2001). Little is known about the regulation of these transporters, but they have been shown to 
play a role in the regulation of adenosine levels in physiological and ischemic conditions 
(Zhang et al., 2011). ENT1 and ENT2 have a large intracellular loop joining transmembrane 
domains 6 and 7, where putative CK2 target consensus sequences are located (Stolk et al., 
2005). These phosphorylation sites suggest that ENT transporter activity and/or membrane 
expression may be subject to modulation by CK2.  
The present study shows that CK2 inhibition with DRB, ENT1 inhibition with NBTI, or 
ENT1/2 inhibition with DPY significantly increased adenosine tone, which corresponds to 
significantly reduced ENT surface expression seen after CK2 inhibition . These results 
indicate that CK2-mediated phosphorylation of ENTs contributes to the regulation of 
extracellular adenosine levels in CA1 of the hippocampus. This represents a potentially 
important mechanism for neuroprotective therapy in hypoxic/ischemic neuronal damage. To 
test this potential, propidium iodide-stained slices showed that CK2 inhibitors were 
neuroprotective following a 20min hypoxic insult (Figure 3.3). CK2 activity has been shown 
to decrease in the  hippocampus during ischemic injury, and preventing this decrease has 
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been shown to be neuroprotective (Lee et al., 2004). In contrast, CK2 activity increases in 
brain regions that are resistant to ischemic damage (Bone et al., 2007). This may indicate that 
an endogenous signal, may reduce CK2 levels in ischemic/hypoxic conditions as a protective 
mechanism to enhance neuronal survival.  
ENTs are the most abundant adenosine transporters and control adenosine levels in the 
brain (Noji et al., 2004), and ENT inhibition has been shown to increase extracellular 
adenosine in the hippocampus (Dunwiddie and Masino, 2001). In addition, inhibition of 
adenosine uptake by NBTI and DPY (ENT1 and ENT1/2 inhibitors, respectively) cause 
increased adenosine levels in the olfactory bulb (Sanderson and Scholfield, 1986). Here, we 
show that hippocampal slices pre-incubated with CK2/ENT inhibitors, potentiated fEPSPs 
after 30min DPCPX treatment, indicated that there was higher extracellular adenosine and 
more A1R activation in these slices compared to the control (Figure 3.1). This suggests that 
reduced ENT and CK2 function correspond to increased extracellular adenosine tone in basal 
conditions. With the paired pulse ratios, there was paired-pulse depression in the inhibitor-
treated slices, showing that after DPCPX treatment, there was an increase in the probability 
of neurotransmitter release, showing a presynaptic involvement in both ENTs and CK2 in 
altering adenosine A1R function presynaptically. Because the A1R has a higher binding 
affinity (Kd) for adenosine (70nM) than A2AR (150 nM) (Sanderson and Scholfield, 1986), 
increased adenosine levels by ENT inhibition may predominantly affect A1R-mediated 
synaptic depression but since it also showed increased adenosine tone, the A2A receptor 
could be involved in these excitatory actions. Further studies with the use of A2A receptor 
inhibition would be required to fully elucidate this mechanism.  
The reduced synaptic depression during hypoxia in hippocampal slices pre-treated with 
CK2 and ENT inhibitors indicates that reduced A1R and ENT surface expression after 20min 
hypoxia corresponds to reduced A1R-mediated synaptic depression in hypoxic conditions. So 
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inhibition of CK2 may increase adenosine tone via reduction of ENT1 phosphorylation, 
which induce reduction in ENT1 surface expression and activity (Handa et al., 2001). We 
tested both CK2 inhibitors (DMAT and TBB) and CK2 activator (Spermine or Spermine + 
D-APV) to test potential neuroprotection in hypoxia in hippocampal slices that were stained 
with propidium iodide. DMAT, TBB and Spermine all showed neuroprotection compared to 
hypoxia alone (Figure 3.3).  
Finally, using hippocampal slices taken from rats 48h post-PVD surgery, fEPSP experiments 
showed reduced synaptic potentiation following A1R inhibition with DPCPX. This reduced 
potentiation could indicate that there is less inhibitory tome, possibly due to increased A1R 
desensitization sitization (Coelho et al., 2006) or increased A2AR activity. Importantly, these 
results show that small focal cortical ischemia induces increased adenosine levels in the 
hippocampus, indicating a global effect of focal ischemia in the brain. Further studies are 
required to further elucidate the role of increased adenosine tone in the post-ischemic brain 
after focal ischemia.  
In conclusion, this chapter suggests a role for CK2 in the regulation of adenosine levels in 
the hippocampus. CK2 and ENTs were also shown to be involved in the CA1 hippocampal 
response to hypoxia/reperfusion injury, and CK2 modulation with drug treatments provided 
hippocampal slices with neuroprotection. These results indicate that CK2 may be a viable 
neuroprotective target in ischemia. The implications of a global changes in adenosine 
signaling after focal cortical ischemia may mediate neurodegeneration and neurological 
deficits which can occur after stroke, such as post-stroke dementia (Zhao et al., 2001).  
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4.1 Summary and Discussion 
This thesis explores novel mechanisms contributing to adenosine-mediated 
neuromodulation in the hippocampus in hypoxia and in PVD-induced ischemia. These 
mechanisms suggest potential targets for the development of neuroprotective strategies to 
mitigate ischemia-induced brain damage. Using both fEPSP electrophysiology and 
biotinylation Western blotting techniques using rat hippocampal slices that were given 
various pharmacological treatments, we identify a novel role for PP1, PP2A and PP2B in 
adenosine and hypoxia-induced synaptic modulation in the hippocampus. Propidium iodide 
staining on slices subjected to a hypoxic insult also showed that these protein phosphatases 
mediated hypoxia-induced neurodegeneration while protein phosphatase 1, 2A and 2B 
inhibition was shown to be neuroprotective following a 20min hypoxic insult.. PP1, PP2A, 
and PP2B were shown to regulate A1R-induced GluA1 internalization and subsequent A1R-
induced synaptic depression, whereas only PP2A prevented A1R-induced GluA2 
internalization. After a 20 minute hypoxic insult, normoxic reperfusion induces significant 
adenosine-induced post-hypoxic potentiation (APHP), which is dependent on A2AR-
mediated increased GluA1 expression through PKA activation (Dias et al., 2012). Functional 
fEPSP data shows that inhibition of CK2 has similar effects as inhibition of ENT1 and ENT2 
by increasing adenosine tone and modulating synaptic activity responses during a 20 minute 
hypoxic insult. The data presented in Chapter 3 support the hypothesis that CK2 
phosphorylation of ENT1 regulates the function of ENTs which in turn regulates extracellular 
adenosine tone in the hippocampus. Inhibition of CK2 also provides neuroprotection to 
hippocampal neurons in hypoxia. Finally, PVD focal cortical ischemia induced changes in 
adenosine signaling in CA1 of hippocampal slices 2 days after PVD induction.  
These studies emphasize the importance of adenosine-mediated neuromodulation in 
hypoxic or ischemic conditions, and identify PP1, PP2A, and PP2B as intracellular mediators 
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of adenosine A1 and A2A receptor-induced neuromodulation in the hippocampus during 
hypoxic brain injury. Figure 4.1 summarizes some major mechanisms examined in this thesis 
and the regulatory effects of adenosine in hippocampal neurons.  
 
 
Figure 4.1. Summary of postsynaptic membrane signaling mechanisms examined in this 
thesis. Important summary of the key receptors/proteins and their important physiological 
functions that were elucidated in this thesis and previous publications (Rebholz et al., 2009; 
Chen et al., 2014). Solid black lines indicate the direction of a protein’s action on another, 
and unless otherwise shown, black arrows indicate activation. Dashed lines indicate that 
either a direct or indirect interaction is occurring, and more research is required to describe 
whether there are intermediate steps in these signals. Dark blue arrows indicate the 
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movement of a molecule through a channel. Red lines indicate drug inhibitors and green lines 
indicate drug agonists.  
 
Following ischemic or hypoxic insults to the hippocampus, the particularly vulnerable 
CA1 region is prone to profound synaptic depression and neurodegeneration (Pellegrini-
Giampietro et al., 1992; Dale et al., 2000). Due to the essential role of the hippocampus in 
multiple learning and memory processes, neurodegeneration in this area can have a 
widespread deleterious effects  on memory and cognition, and has been linked to a condition 
known as post-stroke dementia (Zhao et al., 2001). Development of neuroprotective 
treatments is imperative and of the utmost concern (Gladstone et al., 2002). Recent 
developments show that adenosine is a major neuromodulator during noxious events in the 
brain, and defining the widespread actions of adenosine through the family of adenosine 
receptors may lead to novel targets for neuroprotection in stroke and other neurodegenerative 
disorders (Boison, 2006; Shen et al., 2011; Pedata et al., 2013). Based on the hypothesis that 
small strokes may contribute to increased risk of post-stroke demetia (Zhao et al., 2001) 
Adenosine-mediated changes in the hippocampus through the intracellular actions of the 
adenosine A1 (A1R) and A2A (A2AR) receptors are the main focus of this thesis. Through 
utilizing multiple pharmacological agents along with hypoxia experiments on hippocampal 
slices and PVD focal cortical ischemia, the effects of three major serine/threonine 
phosphatases, PP1, PP2A and PP2B were shown to mediate adenosine A1R-induced synaptic 
depression through producing AMPA receptor subunit GluA1, and to a smaller extent GluA2, 
intnernalization in the hippocampus. Additionally, CK2 inhibition was shown to have similar 
effects as equilibrative nucleoside transporter (ENT) inhibition, which was to increase 
extracellular adenosine tone, thus increasing A1R-mediated synaptic depression in CA1 of rat 
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hippocampal slices. Finally, CK2 inhibition was shown to be neuroprotective after 20min 
hypoxia.  
In chapter 2, we investigated the role of protein phosphatases 1, 2A and 2B in adenosine-
mediated synaptic depression with selective A1R agonist treatment and hypoxia/reperfusion 
injury in rat hippocampal slices. These three phosphatases were shown to mediate A1R-
induced GluA1 endocytosis by modulating the phosphorylation of Ser831 and Ser845 GluA1 
C-terminal resudues, two known regulatory sites of GluA1 which modulate GluA1 surface 
expression and synaptic translocation (Roche et al., 1996; Lee et al., 2003). Protein 
phosphatase 1, 2A and 2B inhibition reduced CPA-induced GluA1 internalization, but only 
PP2A inhibition prevented CPA-induced GluA2 endocytosis. Along the same trend, the 
levels of GluA1 pSer831 and pSer845 were reduced by CPA, and this reduction in pSer831 
and pSer845 was prevented by pre-treatment of hippocampal slices with PP1, PP2A and 
PP2B inhibitors. Along with reducing AMPAR surface expression, 30min A1R activation 
induced APSD (Chen et al., 2014), which was reduced by protein phosphatase inhibitor pre-
treatment. Taken together with previous work, p38 MAPK and JNK along with PP1, PP2A 
and PP2B appear to have differential regulatory actions on GluA1- and GluA2-containing 
AMPAR surface expression (Chen et al., 2014). Importantly, we show that protein 
phosphatase inhibitor treatment to hippocampal slices promotes neuroprotection in the 
hippocampus following 20min hypoxia (Figure 2.8), implicating protein phosphatase activity 
induced by A1R activation in pro-apoptotic intracellular signaling.  
Although adenosine A1Rs have been accepted as a neuroprotective adenosine receptor, 
these data suggest that although acute A1R-induced synaptic depression in ischemia may be 
neuroprotective, the long-term intracellular changes induced by A1R activation induce 
neurodegeneration and that inhibition of A1R-activated intracellular proteins provides 
neuroprotection to hippocampal neurons. We suggest that chronic changes caused by 
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adenosine A1R signaling may enhace neurodegeneration in the hippocampus. These studies 
show that inhibition of PP1, PP2A, and PP2B were neuroprotective and prevented A1R-
induced GluA1 internalization.  
To examine these effects in hypoxia-reperfusion conditions, hippocampal slices were 
subjected to a 20min hypoxic insult followed by a 45min normoxic washout/reperfusion 
period. After hypoxia, both control and protein phosphatase inhibitor-treated hippocampal 
slices showed fEPSP recovery in normoxic reperfusion above baseline, or APHP (Figure 
2.4). Treatment with SCH442415 (5nM), an A2AR antagonist, prevented APHP (Figure 2.7), 
indicating that A2AR activation following reperfusion mediates APHP. Slices subjected to 
20min hypoxia followed by 45min normoxic washout showed increased surface GluA1, but 
not GluA2, levels during reperfusion-induced APHP, which was prevented by pre-treatment 
with SCH442416 (Figure 2.5). Increased GluA1 surface expression after 45min washout also 
corresponded to increased pSer831 and pSer845 levels, which was also prevented with 
SCH442416 treatent (Figure 2.6). This thesis describes a novel mechanism where PP1, 
PP2A, and PP2B mediate the functional interaction between A1Rs and GluA1, where protein 
phosphatases induced GluA1-containing AMPARs. It also suggests a pro-neurodegenerative 
role of excess protein phosphatase activity in neuronal insult conditions. Previous studies 
have described the involvement of PP1, PP2A and PP2B in various hypoxia, oxygen-glucose 
deprivation, or ischemia models (Rundén et al., 1998; Cid et al., 2007), and their inhibition 
has been implicated in neuroprotection. In this study, we add to the wide list of functions 
performed by these three ubiquitous protein phosphatases.  
Recently, Dias et al. showed that 10min oxygen-glucose deprivation (OGD) to 
hippocampal slices caused reduced excitatory postsynaptic currents (EPSCs) followed by 
increased recovery above baseline levels (potentiation), which has been termed ischemia-
induced long-term potentiation (i-LTP) (Dias et al., 2013). The results from fEPSP hypoxia 
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studies performed in this thesis mimicked the effect seen by Dias et al. (2013), showing 
significant synaptic depression in hypoxia followed by fEPSP potentiation during normoxic 
reperfusion. Both i-LTP and APHP involve A2AR activation and increased CP-AMPAR 
activity, and potentiation can be reduced by either A2AR inhibition or CP-AMPAR inhibition 
(Dias et al., 2013). These data indicate that GluA1-containing AMPARs and A2ARs are key 
mediators of reperfusion injury to neurons by inducing increased Ca2+ permeability and 
cellular excitability, thus increasing the chance of excitotoxicity. Additionally, hypoxia 
reduced GluA2 surface expression which did not increase after reperfusion. Reduced GluA2 
surface expression has been associated with neurodegeneration through apoptotic pathways 
(Pellegrini-Giampietro et al., 1997) 
Although the mechanism by which adenosine induces neuromodulatory effects in the 
hippocampus are not fully understood, this study further emphasizes the importance of this 
essential molecule in hypoxic insult conditions in the hippocampus. GluA1 is the most 
abundantly expressed AMPAR subunit and confers Ca2+-permeability (Rogers et al., 1991). 
Increase CP-AMPAR surface expression is a known mechanism for the induction of LTP 
(Szabo et al., 2012), which shows similarities to i-LTP, except that CP-AMPAR expression is 
transient in LTP, whereas it is more prolonged in i-LTP (Szabo et al., 2012), which may 
explain why CP-AMPAR expression is not neurotoxic in LTP induction.  
The experiments performed in Chapter 3 further investigate adenosine-induced 
neuromodulation through the regulation of extracellular adenosine by ENTs. Since ENTs are 
passive and equilibrative, their action is largely regulated by the modulation of their surface 
expression (Parkinson et al., 2011). Since ENT1 contains CK2 consensus sequences, it 
follows that CK2 may play a role in the adenosine-induced modulation of ENT1 surface 
expression, which when reduced as it is in ischemia, may enhance neurodegeneration (Zhang 
et al., 2011). CK2 also provides a potential intermediary protein for the communication 
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between adenosine A1Rs and ENT1 in the hippocampus (Bone et al., 2007). Results suggest 
that CK2 activity in hypoxia contribute to neurodegeneration following hypoxia, whereas 
inhibition of CK2 prevents hypoxia-induced neurodegeneration. During hypoxia, A1Rs 
become desensitized (Dixon et al., 1997; Coelho et al., 2006), which would reduce A1R-
mediated effects including increased CK2 activity. CK2 is a negative regulator of A2ARs 
(Rebholz et al., 2009), meaning that reduced CK2 activity increases A2AR activity. These 
results indicate that CK2 may mediate a sort of cross-talk between A1 and A2A receptors.  
 
4.2 Future directions 
One of the most important immediate future directions is to further classify the 
intracellular mechanisms described in this research by using a specific tat-peptide knockdown 
technique both in acute hippocampal slices and in PVD stroke. In fact, we are currently 
exploring these mechanisms using a tat-peptide interference technique with peptides YP and 
YD, which are designed to inhibit the function of CK2 and PP2A, respectively.  
Additionally, studies should be performed to examine the potential neuroprotective effects 
of the drug inhibitors used in these studies by classifying hypoxia- and ischemia-induced 
neurodegeneration in the hippocampus. Similar propidium iodide staining experiments 
should also be done with 30min CPA treatment to test whether CPA induces any 
neurodegeneration. Finally, the role of CK2 as a potential mediator of A1R and A2AR cross-
talk will be further explored using fEPSP, confocal imaging and Western blotting techniques.  
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